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1.    INTRODUCTION 
Gastrointestinal disease due to inflammation of the gastrointestinal mucosa is a 
common problem in dogs. A definitive diagnosis of inflammatory bowel disease 
(IBD) is often challenging and requires invasive and expensive procedures. Also, an 
objective assessment of disease severity and disease progression can be difficult. 
Therefore, it is highly desirable to develop non-invasive, inexpensive, yet accurate 
methods for the objective assessment of severity of intestinal inflammation.  
Neutrophil elastase (NE) is a protein released by activated polymorphonuclear 
granulocytes. This protein plays a significant role in endothelial cell injury mediated 
by neutrophils (Smedly et al., 1986). Neutrophil elastase belongs to the group of 
serine proteinases and is a major component of azurophil granules within the 
neutrophils (Barrett, 1981). Neutrophil elastase has previously been purified in several 
species including humans and dogs (Boudier et al., 1982; Cotter et al., 1980; 
Delshammar et al., 1976; Dubin et al., 1994; Geiger et al., 1985; Marossy et al., 1980; 
Mistry et al., 1999; Ohlsson et al., 1976; Taylor et al., 1975). In some human patients 
with IBD the gastrointestinal mucosa contains a large number of neutrophils and, 
therefore, it is not surprising that many studies have been conducted to assess 
different neutrophil-derived markers as a tool for assessment of intestinal 
inflammation (Dwarakanath et al., 1997; Poullis et al., 2002). The concentration of 
neutrophil elastase in feces and serum has been used as a marker for the assessment of 
human IBD (Adeyemi et al., 1985; Andus et al., 1993). Such a marker might also 
prove to be useful in canine patients with IBD. 
 
1.1 Hypothesis and objectives 
The hypothesis of this study was that NE might be a useful marker for the assessment 
of canine patients with IBD. In order to prove or disprove this hypothesis, the 
objectives of this study were: 1. to purify NE from dog blood, 2. to develop and 
validate an immunoassay for measurement of canine NE (cNE) in serum, and 3. to 
compare serum concentrations of cNE between healthy dogs, and dogs with 
inflammatory bowel disease. 
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2.    LITERATURE REVIEW 
2.1.    Neutrophil Elastase (NE) 
Neutrophils are essential for host defense against invading pathogens. They engulf 
and break down microorganisms using an array of mechanisms, such as reactive 
oxygen species and antimicrobial peptides and proteases, including NE, cathepsin G 
and proteinase 3 (Pham, 2006). Neutrophil elastase is located in the azurophil 
granules of polymorphonuclear leukocytes (Bode et al., 1989). Elastin is one of the 
many physiological substrates of NE (Bieth et al., 1973). The proteolytic activity of 
NE is essential for the migration of neutrophils through connective tissue (Bode et al., 
1989). If not regulated properly by its natural inhibitors, neutrophil elastase can lead 
to severe damage by hydrolyzing connective tissue proteins (Travis, 1988). 
Neutrophil elastase has been isolated and purified in many species including humans, 
cows, pigs, sheep, horses, hamsters, rabbits and dogs (Boudier et al., 1982; Cotter et 
al., 1980; Delshammar et al., 1976; Dubin et al., 1994; Geiger et al., 1985; Marossy et 
al., 1980; Mistry et al., 1999; Ohlsson et al., 1976; Taylor et al., 1975). 
Table 1 summarizes different biochemical characteristics of neutrophil elastase from 
different species. 
  
2.1.1.    Nomenclature 
Neutrophil elastase ([E.C. 3.4.21.37]; classification is proposed by the international 
union of biochemistry and molecular biology) belongs to the family of serine 
endopeptidases. In the literature many synonyms for neutrophil elastase can be found, 
such as leukocyte elastase, lysosomal elastase, polymorphonuclear leukocyte elastase, 
elastase, elaszym, serine elastase, and granulocyte elastase.  
The group of elastases, which includes neutrophil and pancreatic elastase, has the 
ability to cleave the connective tissue protein elastin, which serves as the amorphous 
component of elastic fibers (Janoff et al., 1968). Elastin is widely distributed in 
vertebrate tissues, and is especially abundant in lung, skin, arteries, and ligaments. 
Neutrophil elastase differs from pancreatic elastase in it's specificity towards synthetic 
substrates and also in inhibitor sensitivity (Bode et al., 1989). 
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In the literature the term “proteinase” and “protease” are often used synonymously. 
However, this is incorrect based on the nomenclature proposed by the International 
Union of Biochemistry and Molecular Biology (IUBMB). Briefly, the term protease 
comprises two groups of enzymes: the endopeptidases and the exopeptidases. In 
contrast, the term proteinase only refers to endopeptidases. Four mechanistic classes 
of proteinases are recognized by the IUBMB: 1) serine proteinases, 2) cysteine 
proteinases, 3) aspartic proteinases, and 4) metallo proteinases. 
Exopeptidases remove amino acids sequentially from either the N- or C-terminus. In 
contrast, endopeptidases catalyze the hydrolysis of peptide bonds in the interior of 
proteins (Enzyme Nomenclature, 1984). 
       LITERATURE REVIEW 
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     Table 1: Differences in biochemical characteristics of neutrophil elastase from different species 
Species Molecular 
Weight  
Isoelectric 
Point 
Optimum pH Different 
Isoforms 
Starting 
Material 
Literature 
Human 
22,000 
22,000 
8.77-9.15 
not reported 
8.3 
not reported 
yes (4) 
yes 
blood 
blood 
(Taylor et al., 1975) 
(Feinstein et al., 1975) 
Horse 
20,500- 
24,500 
8.8-10 7.0-10.0 yes (2) blood (Dubin et al., 1976) 
Cow 33,000 not reported not reported no  blood (Marossy et al., 1980) 
Sheep 26,000 not reported  8.0 no blood (Mistry et al., 1999) 
Pig 27,000 > 8 8.0 not reported  blood (Geiger et al., 1985) 
Hamster not reported not reported not reported not reported blood (Boudier et al., 1982) 
Rabbit 25,000 5.9 7.5-8.5 no blood (Cotter et al., 1980) 
Dog 24,800 not reported 8.0-8.5 no  
induced 
peritonitis (Delshammar et al., 1976) 
LITERATURE REVIEW 
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2.1.2.    Structure 
Human neutrophil elastase is a glycoprotein that consists of a single polypeptide chain 
of 218 amino acids residues (Bode et al., 1989). Comparison of the amino acid 
sequence of neutrophil elastase to other elastolytic serine proteases shows only 
moderate homology to porcine pancreatic elastase (40% homology) (Bode et al., 
1989), human pancreatic elastase I (43% homology) (Tani et al., 1988), or human 
neutrophil cathepsin G (37% homology) (Sinha et al., 1987). 
In contrast to human neutrophil elastase, canine neutrophil elastase molecule lacks 
carbohydrates (Delshammar et al., 1976). The protein consists of 282 amino acids and 
does not contain any tyrosine and lysine. The amino acid sequence of canine 
neutrophil elastase is shown in table 2. 
 
 
Table 2: Amino acid sequence of canine neutrophil elastase.  
This figure shows the complete amino acid sequence of canine neutrophil elastase as 
published by the canine genome project. The sequence is shown using a one-letter 
code: A=alanine, C=cysteine, D=aspartic acid, E=glutamic acid, F=phenylalanine, 
G=glycine, H= histidine, I=isoleucine, L=leucine, M=methionine, N=asparagine, 
P=proline, Q=glutamine, R=arginine, S=serine, T=threonine, V=valine, 
W=tryptophan 
 
 
   
   1  MTARRVPAGP  ALGPLLLLAT   LLPGPALASE   IVGGRPAQPH  AWPFMVSLQR  RGGHFCGGTL    
 61   IAPNFVMSAA  HCVDGLNFRS  VVVVLGAHDL  GERESTRQLF AVQRVFENGF  DPVRLVNDIV 
121  LLQLNGSATI  NANVQVARLP   AQNQGVGNGV   QCLAMGWGQL  GTAQPPPRIL QELNVTVVTT   
181  LCRRSNVCTL  VPRRRAGICF  GDSGGPLVCN  GLIQGIDSFI  RGSCASGFFP  DAFAPVAQFV  
241  DWINSIIRRP  PALPPARPGQ  QDPERGAARA  PPPAPHRPRP   TQ 
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2.1.3.    Function 
Stored in azurophil granules, human neutrophil elastase is sequestered in the cell as an 
active enzyme bound to an inert polysaccharide matrix (Del Mar et al., 1980). 
Neutrophil elastase plays a part in mediating the defense response to inflammation. 
During phagocytosis neutrophil elastase is released into the extracellular space.  
Neutrophil elastase degrades connective tissue proteins, including elastin, collagens 
and proteoglycans (Janoff, 1985a). In addition to connective tissue proteins, many 
plasma proteins, such as immunoglobulins, clotting factors and complement proteins, 
can be hydrolyzed by neutrophil elastase (Janoff, 1985a). This is accomplished 
through the cleavage of peptide bonds in the target protein. The specific peptide bonds 
cleaved by neutrophil elastase are those on the carboxy side of small hydrophobic 
amino acids, especially valine and to a lesser extent alanine (Barrett, 1981). The 
proteolytic effect of neutrophil elastase is enhanced by the presence of other 
neutrophil derived proteins, such as lysozyme and cathepsin G (Boudier et al., 1981). 
In addition, platelet factor 4, heparin,  and high ionic strength in the solution are able 
to enhance the elastolytic activity of neutrophil elastase (Boudier et al., 1980). 
Neutrophil elastase activates bactericidal/permeability-inducing protein (BPI) by 
cleaving the active amino terminal portion of BPI from the intact holoprotein 
(Edwards, 1994). The active form of BPI is then able to destruct the Outer membrane 
protein A (OmpA) of E. coli and other Gram-negative bacteria (Edwards, 1994).  
The catalytic function of neutrophil elastase is mediated by the catalytic triad. The 
catalytic triad refers to the active site of the enzyme, consisting of the amino acids 
histidine (His-57), serine (Ser-195) (therefore the name serine proteinases), and 
aspartic acid (Asp-102) (Kraut, 1977). The purpose of this arrangement of amino 
acids in the active site is presumably to make the serine sufficiently nucleophilic to 
attack the carbonyl (C=O) carbon of the substrate, thus setting of the catalytic process 
(Daggett et al., 1991).  
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2.1.4.    Inhibition of neutrophil elastase 
During phagocytosis and neutrophil turnover, NE is released into the extracellular 
space. If NE function  is not regulated properly NE can be extremely destructive, due 
to its capability of degrading many connective tissue proteins, including elastin, 
collagen, and proteoglycan (Janoff, 1985a). Under physiological conditions NE 
function is tightly regulated by circulating plasma proteinase inhibitors. The primary 
physiological inhibitor of NE is α1-proteinase inhibitor (α1-PI), a glycoprotein, 
synthesized in the liver, with a molecular weight of approximately 52,000 (Janoff, 
1985a). In normal individuals α1-PI inactivates any elastase released from neutrophils, 
either within the circulation or also outside the circulation. This inactivation leads to 
the formation of a stable, irreversible complex between the inhibitor and the 
proteinase (Nakajima et al., 1979). Neutrophil elastase binds to the active site of α1-
proteinase inhibitor with subsequent formation of a sodium dodecyl sulfate-stable 
linkage between the inhibitor and the enzyme (Nakajima et al., 1979). In this reaction 
a methionyl bond is cleaved, and it has been shown that NE has a high activity against 
other methionyl substrates (Travis et al., 1979). Oxidized forms of methionine 
residues in the α1-PI molecule, which have been converted to a methionine sulfoxide 
residue, are resistant to proteinases like neutrophil elastase (Travis et al., 1979). 
Alpha1-PI deficiency and cigarette smoke are both major risk factors for the 
development of pulmonary emphysema, a main component of chronic obstructive 
pulmonary disease in humans (Shapiro et al., 2003). Janoff et al. demonstrated that 
smoke vapor inactivates α1-PI, due to the formation of oxidized methionine residues 
(Janoff et al., 1977). 
Alpha2-macroglobulin represents the second most important defense mechanism 
against NE. It is not as effective as α1-PI, because due to its molecular mass of 
750,000 Daltons its activity is restricted to controlling proteinase activity within the 
circulation. Besides NE, alpha2-macroglobulin inactivates a variety of other 
proteinases such as seryl-, cysteinyl-, aspartyl- and metallo-proteinases (Travis, 
1988). 
LITERATURE REVIEW 
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2.2.    Neutrophil elastase and disease 
2.2.1.    Alpha1-proteinase inhibitor deficiency 
Neutrophil elastase is inhibited by the protein alpha-1-proteinase inhibitor (α1-PI), 
which binds neutrophil elastase covalently in a ratio of 1:1. Thus, alpha1-PI deficiency 
leads to uninhibited destruction of elastic fiber by NE. The deficiency of α1-PI was 
first described in 1963 (Laurell et al., 1963). The term α1-PI deficiency describes the 
condition that fulfills the following criteria: 1) serum analysis reveals no α1-band in 
the electrophoretic strip, 2) on agar gel immunoelectrophoresis only traces of α1-PI 
are visible, which also show reduced mobility, and 3) all other serum proteins appear 
to be normal (Eriksson, 1965). 
Alpha1-PI deficiency is one of the most common inherited metabolic disorders in 
humans with the potential to cause severe injury to at least two organ systems, namely 
the lung and the liver (Graziadei et al., 1998). Severe α1-PI deficiency is associated 
with the development of pulmonary emphysema in early or mid-life (Snider, 1989). 
Several studies in animal models have shown that an imbalance between proteinases 
(mostly NE) and anti-proteases in the lung causes the actual emphysema (Janoff, 
1985b; Snider et al., 1986). 
The gene for α1-PI deficiency is located on chromosome 14 and is expressed in 
codominant fashion (Darlington et al., 1982). The phenotype of α1-PI is determined 
by two independent expressions of the two parental alleles (Snider, 1989). Over 30 
different biochemical variants of α1-PI exist, and these are classified in the Pi system 
(Pi stands for “proteinase inhibitor”). Variants are designated by a capital letter 
corresponding to their mobility on isoelectric focusing (Hutchison, 1988). The most 
common variant is the M type. Other types are S and Z. In the S and Z types, 
abnormalities arise from a single amino acid substitution in the primary chain and 
result in decreased or undetectable α1-PI concentrations in serum (Hutchison, 1988). 
Homozygotes of the Z type have been most commonly implicated in the pathogenesis 
of pulmonary emphysema (Eriksson, 1965). 
The pathophysiology of lung injury in α1-PI deficient patients is due to a deficiency of 
antiprotease activity and uninhibited proteolytic attack by NE on elastin in the lung 
(Graziadei et al., 1998). Hepatic injury in α1-PI deficient patients is linked to 
LITERATURE REVIEW 
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intracellular accumulation of mutant α1-PI, mainly within the endoplasmatic reticulum 
(Graziadei et al., 1998). 
 
2.2.2.    Hereditary neutropenia 
Inherited neutropenia is a rare disease in humans, consisting of two main forms: 
cyclic neutropenia (CN) and severe congenital neutropenia (SCN) (Haurie et al., 
1998). 
Human CN is caused by an autosomal dominant defect, and is characterized by 
fluctuating neutrophil counts over a 21 day period (Haurie et al., 1998). Neutrophil 
counts can vary from undetectable to almost physiological numbers (Lange, 1983). 
The periodical fluctuation between high and low neutrophil counts in CN is proposed 
to be caused by a feedback mechanism, by which mature neutrophils inhibit 
progenitor cells (Horwitz et al., 2003b). Inhibition of progenitor cells leads to a loss of 
successive cohorts of maturing cells, eventually depleting the generation of cells 
producing the inhibitory signal, thus allowing the pattern to repeat (Horwitz et al., 
2003a). In turn, patients with low neutrophil counts are predisposed to opportunistic 
infections. 
Severe congenital neutropenia refers to a non-cyclical neutropenia present at birth. 
Characteristic for SCN is that the bone marrow displays a pro-myelotic arrest 
(Horwitz et al., 2003b). Myelodysplasia and acute myelogenous leukemia frequently 
complicate SCN (Horwitz et al., 2004). 
In 1999 Horwitz et al. reported that mutations in the ELA2 gene, the gene encoding 
NE, causes both CN and SCN in humans (Horwitz et al., 1999). A total of 30 different 
mutations in ELA2 have been identified (Horwitz et al., 2003b). Characterization of 
the biochemical properties of the mutant NE has been performed by recombinant 
expression of the mutated ELA2 in rat basophilic leukemia cells (Li et al., 2001). 
Most of the mutant forms of NE have no consistent effect on proteolytic activity (Li et 
al., 2001), and no obvious change in substrate specificity and protein stability 
(Horwitz et al., 2004). The mutant NE differs in its susceptibility to inhibition by α1-
PI (Horwitz et al., 2004). None of these properties were consistent in all mutants.  
Recent findings of Benson et al. demonstrate a homozygous mutation of AP3B1, 
which encodes the β-subunit of the adaptor protein complex 3 (AP3), which has been 
LITERATURE REVIEW 
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suggested as the cause of canine CN and suggests that CN could serve as a model for 
the molecular basis of hereditary neutropenia (Benson et al., 2003). 
Canine cyclic neutropenia is also known as the Gray Collie Syndrome, because it was 
first described in this breed, and affected dogs have a hypopigmented coat (Lothrop, 
Jr. et al., 1987).  
The canine and human forms of this disease differ in some points: 1) human patients 
with CN do not show signs of pigment abnormalities, 2) the disease demonstrates an 
autosomal-recessive transmission in the dog, 3) neutrophil counts cycle every two 
weeks in the dog versus every three weeks in humans (Horwitz et al., 2004), and 4) 
proteolytic activity of NE is reduced in humans (Horwitz et al., 2004) and nearly 
undetectable in dogs (Benson et al., 2003). DNA sequencing and genetic linkage 
analysis excluded ELA2 mutations as the cause of the Gray Collie Syndrome in dogs 
(Benson et al., 2003).  
The adaptor protein complex 3 resides on the cytoplasmic surface of membrane-
bound vesicles and directs subcellular trafficking of membrane cargo proteins (Boehm 
et al., 2002). Mutations of the β-subunit of AP3 result in cargo proteins being 
localized incorrectly in the plasma membrane (Dell'Angelica et al., 1999). Neutrophil 
elastase is an AP3 cargo protein (Benson et al., 2003). Mutations in either NE or the 
β-subunit of AP3 result in similar disease phenotypes (Horwitz et al., 2004) as are 
seen in human CN and SCN as well as in the Gray Collie Syndrome. 
 
 
2.2.3.   Neutrophil elastase as a marker of disease severity of inflammatory bowel 
disease in humans 
Human NE, which is stored in the azurophil granules of polymorphonuclear 
neutrophils is released into the extracellular space during the process of phagocytosis 
(Bode et al., 1989). It plays an important role in endothelial cell injury mediated by 
neutrophils (Smedly et al., 1986). 
There are two forms of human IBD, ulcerative colitis and Crohn’s disease. 
Neutrophilic infiltration is a reliable histological finding in patients with ulcerative 
colitis and is frequently seen in patients with Crohn’s disease, suggesting that NE may 
contribute to the pathogenesis of IBD (Adeyemi et al., 1985). Several studies have 
been performed to evaluate the utility of NE in the assessment of human patients with 
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IBD (Adeyemi et al., 1985; Adeyemi et al., 1992; Andus et al., 1993; Fischbach et al., 
1987). 
Adeyemi et al. measured human NE concentrations in the plasma of 56 patients with 
Crohn’s disease (31 active/25 quiescent disease)  and in 38 patients with ulcerative 
colitis (23 active/15 quiescent disease) (Adeyemi et al., 1985). The mean NE 
concentration in plasma in patients with active Crohn’s disease was significantly 
greater than in patients with active ulcerative colitis (p=0.013) (Adeyemi et al., 1985). 
Plasma NE concentrations in quiescent IBD were significantly lower, compared to 
active IBD (p=0.0001 for Crohn’s disease, and p=0.0014 for ulcerative colitis) 
(Adeyemi et al., 1985). Also, the concentrations of plasma NE correlated with serum 
C-reactive protein concentrations (p<0.05 for ulcerative colitis; p<0.01 for Crohn’s 
disease) (Adeyemi et al., 1985). Furthermore, NE concentrations correlated 
significantly with the Crohn’s disease activity index scores (p<0.005) (Adeyemi et al., 
1985). The conclusions of this study were that the plasma concentration of NE in 
patients with IBD reflects the disease activity of their intestinal disease and repeated 
measurements might be useful in the assessment and clinical progression of these 
patients (Adeyemi et al., 1985). 
Andus et al. measured serum and fecal NE concentrations in 70 patients with Crohn’s 
disease and 24 patients with ulcerative colitis with different disease activity indices 
(Andus et al., 1993). The plasma NE concentrations were significantly higher in 
patients with active disease than in those that did not have active disease (p=0.0017 
for Crohn’s disease, and p=0.026 for ulcerative colitis) (Andus et al., 1993). Plasma 
and fecal NE concentrations correlated in patients with Crohn’s disease p<0.01, but 
not in those with ulcerative colitis (p=0.05) (Andus et al., 1993). The correlation of 
disease activity and fecal NE concentration was significant in patients with ulcerative 
colitis (p=0.002), but not in those with Crohn’s disease (Andus et al., 1993). Andus et 
al. concluded from their study that NE can be measured in plasma as well as in feces 
of patients with active IBD. Plasma concentrations reflect the disease activity in IBD 
patients (Andus et al., 1993), but due to the variation of the data and the large overlap 
between different groups the clinical value of this test in humans is questionable. 
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2.3.    Diagnosis of idiopathic inflammatory bowel disease in dogs 
Canine idiopathic IBD is a group of disorders characterized by persistent or recurrent 
gastrointestinal tract disease associated with histological evidence of inflammation of 
the lamina propria of the small and/or large intestine without any identifiable cause 
(Guilford, 1996b). The pathogenesis of IBD is ill-defined, but it is likely immune 
mediated with environmental and genetic factors contributing to the expression of this 
disease (Fiocchi, 1998). Inflammatory bowel disease is classified according to the 
predominant type of inflammatory cell present in the histopathological specimen and 
the area of the intestine affected (Jergens, 1999). The most common form described is 
lymphocytic-plasmacytic enteritis (Jergens et al., 1992). Also, frequently occurring 
are eosinophilic gastroenterocolitis and granulomatous enteritis (Jergens et al., 1992).  
The most prominent clinical signs associated with canine idiopathic IBD are chronic 
vomiting and/or diarrhea (in severe cases hematemesis and/or hematochezia or 
melena), altered appetite, abdominal discomfort/pain, excessive borborygmus and 
weight loss (Hall et al., 2005). 
Before a diagnosis of idiopathic IBD can be made, a variety of other diseases that may 
cause intestinal inflammation have to be ruled out. The major differential diagnoses 
for IBD are: 1) chronic infection (e.g., Giardia sp., Histoplasma sp., Toxoplasma sp., 
Mycobacteria sp., protothecosis, pythiosis, or pathogenic bacteria), 2) food allergy, 
and 3) bowel inflammation associated with other primary gastrointestinal diseases 
(e.g., lymphoma and lymphangiectasia) (Hall et al., 2005). Jergens et al. (Jergens et 
al., 2003) developed a scoring index for disease activity in canine patients with 
idiopathic IBD, the canine IBD activity index (CIBDAI). The CIBDAI is useful in the 
management of clinical patients with IBD by helping assessing the response to 
treatment, as well as long term progress (Jergens et al., 2003). 
The gold standard for the diagnosis of idiopathic IBD is endoscopy and 
histopathologic evaluation of intestinal biopsies (Guilford, 1996b). Because of the 
disadvantages of these modalities, such as invasiveness of the procedure, high intra- 
and inter-observer variation on histopathologic evaluation, and the financial aspect, 
new diagnostic approaches are desirable (Willard et al., 2002).  
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2.3.1    Serologic markers for canine IBD 
Recent studies examined different serologic markers such as perinuclear 
antineutrophilic cytoplasmic antibodies (pANCA) (Luckschander et al., 2006), and 
serum acute-phase proteins, such as C-reactive protein (CRP), haptoglobin (HAP), α-
acid glycoprotein (AGP) and serum amyloid A (SAA) (Jergens et al., 2003) for their 
usefulness as a diagnostic tool for IBD. 
Luckschander et al. (Luckschander et al., 2006) examined a group of 65 dogs for the 
presence of pANCA. Of these 65 dogs, 39 dogs had food- responsive diarrhea (FRD) 
and 26 dogs had idiopathic IBD. In the FRD group the percentage of pANCA positive 
dogs (62%) was significantly (p=0.002) higher compared with the IBD group (23%). 
There was no difference in pANCA titers between the groups after appropriate 
treatment. No correlation between pANCA status in FRD or IBD dogs before 
treatment and scores for CIBDAI, endoscopy, or histopathology before or after 
treatment was observed (Luckschander et al., 2006). 
Jergens et al. compared the serum concentrations of CRP, HAP, AGP, and SAA with 
the CIBDAI in 58 dogs with IBD (Jergens et al., 2003). Concentrations of SAA were 
significantly (p<0.001) higher in healthy dogs than in dogs with IBD. CRP and AGP 
concentrations were higher in IBD dogs compared to healthy dogs. The best 
correlation with the CIBDAI was observed when HAP and histology scores where 
compared (p<0.001) (Jergens et al., 2003). During the 2 to 3 weeks post-treatment 
period HAP was significantly (p<0.0001) increased, whereas CRP and CIBDAI were 
significantly decreased (p<0.0001), compared to their values prior to treatment 
(Jergens et al., 2003). 
In conclusion: although these assays might be useful in some cases, they have not 
been found to be particularly helpful in diagnosing, monitoring, and predicting the 
outcome of idiopathic IBD in dogs. As a result, the need for new non-invasive tests 
for canine idiopathic IBD still remains.  
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3.    MATERIALS AND METHODS 
3.1.     Materials 
3.1.1.    Chemicals and reagents 
3,3’,5,5’-tetramethylbenzidine solution  
Pierce Chemical CO, Rockford, IL, 
USA 
Agarose immunodiffusion plate 
Pierce Chemical CO, Rockford, IL, 
USA 
Ammonium sulfate Sigma Chemicals, St. Louis, MO, USA 
Avidin Immuno Pure HABA assay kit 
Pierce Chemical CO, Rockford, IL, 
USA 
Biotin (EZ-Link Sulfo-NHS-LC biotin)  
Pierce Chemical CO, Rockford, IL, 
USA 
Bovine hemoglobin Sigma Chemicals, St. Louis, MO, USA 
Bovine serum albumin  Sigma Chemicals, St. Louis, MO, USA 
Carbonate-bicarbonate buffer  
Pierce Chemical CO, Rockford, IL, 
USA 
Coomassie blue stain 
Pierce Chemical CO, Rockford, IL, 
USA 
Dextran 500  
Accurate Chemicals & Scientific Corp. 
Westbury, NY, USA 
Dimethyl sulfoxide Sigma Chemicals, St. Louis, MO, USA 
NuPAGE 10% Tris-glycine gel Invitrogen, Carlsbad, CA, USA 
IEF anode buffer Invitrogen, Carlsbad, CA, USA 
IEF calibration markers Amersham Biosciences, Piscataway, NJ 
IEF cathode buffer Invitrogen, Carlsbad, CA, USA 
IEF electrophoresis gel pH 3-10 Invitrogen, Carlsbad, CA, USA 
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IEF sample buffer  Invitrogen, Carlsbad, CA, USA 
Immuno Pure Streptavidin HRP-conjugated 
Pierce Chemical CO, Rockford, IL, 
USA 
Molecular weight markers – Mark 12 Invitrogen, Carlsbad, CA, USA 
NuPAGE  MES SDS running buffer Invitrogen, Carlsbad, CA, USA 
NuPAGE  sample reducing agent Invitrogen, Carlsbad, CA, USA 
NuPAGE antioxidant Invitrogen, Carlsbad, CA, USA 
NuPAGE LDS sample buffer Invitrogen, Carlsbad, CA, USA 
Phosphate buffered saline packs 
Pierce Chemical CO, Rockford, IL, 
USA 
Polyoxyethylene sorbitan monolaurate 
(Tween-20)  
Pierce Chemical CO, Rockford, IL, 
USA 
Protein 50 LabChip® kit 
Agilent Technologies GmbH, 
Waldbronn, GER 
Silver stain kit 
Pierce Chemical CO, Rockford, IL, 
USA 
Sodium azide Sigma Chemicals, St. Louis, MO, USA 
Sodium chloride Sigma Chemicals, St. Louis, MO, USA 
Sodium citrate Sigma Chemicals, St. Louis, MO, USA 
Sodium hydroxide Sigma Chemicals, St. Louis, MO, USA 
Sodium metabisulfite  Sigma Chemicals, St. Louis, MO, USA 
Sodium phosphate dibasic Sigma Chemicals, St. Louis, MO, USA 
Sodium phosphate monobasic Sigma Chemicals, St. Louis, MO, USA 
Trichloroacetic acid Sigma Chemicals, St. Louis, MO, USA 
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Tris-Glycine SDS running buffer Invitrogen, Carlsbad CA, USA 
Tris-Glycine SDS sample buffer Invitrogen, Carlsbad CA, USA 
Urea Sigma Chemicals, St. Louis, MO, USA 
Acrylamide Sigma Chemicals, St. Louis, MO, USA 
Glycerol Sigma Chemicals, St. Louis, MO, USA 
Sodium dodecyl sulfate (SDS) Sigma Chemicals, St. Louis, MO, USA 
Trishydroxymethyl-aminomethane (Tris) 
Bio-Rad Laboratories, Hercules, CA, 
USA 
Beta mercaptoethanol Sigma Chemicals, St. Louis, MO, USA 
Bromophenol blue Sigma-Aldrich, St. Luis, MO, USA 
N'N'-bis-methylene-acrylamide (Bis) 
Bio-Rad Laboratories, Hercules, CA, 
USA 
N,N,N',N'-Tetra-methyl-ethylenediamine 
(TEMED) 
Bio-Rad Laboratories, Hercules, CA, 
USA 
Ammonium persulfate (APS) 
Bio-Rad Laboratories, Hercules, CA, 
USA 
iso-amyl alcohol EMD Chemicals Inc., Darmstadt, GER 
PUREGENE RBC lysis solution 
Gentra Systems, Minneapolis, MN, 
USA 
Acetic Acid, glacial EMD Chemicals Inc., Darmstadt, GER 
BCA™ protein assay kit 
Pierce Chemical CO, Rockford, IL, 
USA 
Human elastase Sigma-Aldrich, St. Luis, MO, USA 
Methoxysuccinyl-Ala-Ala-Pro-Val-p-
nitroanilide 
Calbiochem, EMD Biosciences, La 
Jolla, CA, USA 
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3.1.2.    Instruments 
Agilent 2100 Bioanalyzer 
Agilent Technologies GmbH, 
Waldbronn, Germany 
Analog vortex mixer VWR, West Chester, PA, USA 
Centrifuge 5810R Eppendorf, Hamburg, Germany 
Centrifuge GS6R Beckman, Palo Alto, CA, USA 
Centrifuge rotor F 34-6-38 Eppendorf, Hamburg, Germany 
Centrifuge rotor GH 3.8 Beckman, Palo Alto, CA, USA 
Chromatography column – HI Trap® 
Amersham Biosciences, Piscataway, NJ, 
USA 
Chromatography column PD-10, Sephadex 
G-25 M  
Amersham Biosciences, Piscataway, NJ, 
USA 
Chromatography control system -                    
UNICORN - 2.30 
Amersham Biosciences, Piscataway, NJ, 
USA 
Chromatography pump – P-900 
Amersham Biosciences, Piscataway, NJ, 
USA 
Chromatography UV-monitor 900 
Amersham Biosciences, Piscataway, NJ, 
USA 
Chromatography valve PLV-50 
Amersham Biosciences, Piscataway, NJ, 
USA 
Electrophoresis chamber - X-Cell II Invitrogen, Carlsbad, CA, USA 
FPLC - system ÄKTA purifier 
Amersham Biosciences, Piscataway, NJ, 
USA 
Fraction collector Frac-900 
Amersham Biosciences, Piscataway, NJ, 
USA 
Fraction collector, Model 2110 
Bio-Rad Laboratories, Hercules, CA, 
USA 
Mini Prep Cell 
Bio-Rad Laboratories, Hercules, CA, 
USA 
Multipipetter Oxford Fisher Scientific, Pittsburgh, PA, USA 
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Peristaltic Pump, Mini-pump variable flow VWR, West Chester, PA, USA 
pH-meter – model 8010 VWR, West Chester, PA, USA 
Pipettes P-10, P-20, P-100 Rainin, Woburn, MA, USA 
Pipettes P-250, P-1000, P-5000 Rainin, Woburn, MA, USA 
Plate incubator/shaker Stat Fax©-2200  
Awareness Technology Inc., Palm State, 
FL, USA 
Power Pac 3000 Power Supply, 220/240 V 
Bio-Rad Laboratories, Hercules, CA, 
USA 
SOFTMAX PRO analysis software package 
Molecular Devices, Sunnyvale, CA, 
USA 
Spectrophotometer, Ultrospec 2000 Pharmacia Biotech, Cambridge, UK 
Statistical software package Prism 3.0  GraphPad Software Inc., San Diego, CA 
Tissue grinder Polytron PT-2100  Kinematica AG, Luzern, Switzerland 
Ultrasonic homogenizer, Model 300 V/T BioLogics, Inc., Manassas, VA, USA 
UV MAX ELISA plate reader    
Molecular Devices, Sunnyvale, CA,  
USA 
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3.1.3.   Disposables 
Blood collection bottles, evacuated, with 
anticoagulant ACD solution 
The Metrix Company, Dubuque, IA, 
USA 
Centrifugal filter devices - Centripep YM-
10 
Amicon Bioseparations, Bedford, MA, 
USA 
Centrifugal filter devices - Centripep YM-3 
Amicon Bioseparations, Bedford, MA, 
USA 
Centrifugal filter devices -Amicon Ultra - 4                   
5,000 MWCO 
Millipore Corporation, Bedford, MA, 
USA 
Culture tubes 12 x 75 mm VWR, West Chester, PA, USA 
Dialysis cassettes - Slide-A-Lyser 2K Pierce, Rockford, IL, USA 
ELISA plates Combi plates 8 Labsystems, Helsinki, Finland 
Membrane filters 3 µm – 0.45 µm 
Pall – Gelmann Sciences, Ann Arbor, 
MI, USA 
Pleated dialysis tubing – Snakeskin 10k 
MW Pierce, Rockford, IL, USA 
Self-Standing centrifugal tubes,  
polypropylene, 50 ml 
Corning Incorporated, Corning, NJ, 
USA 
EZ Flip™ centrifugal tubes, 15 ml Nalge Nunc International, USA 
Blue Max™ Jr., conical polypropylene tube, 
15 ml Falcon, Franklin Lakes, NJ, USA 
Protein assay chips, protein 50 
Agilent Technologies GmbH, 
Waldbronn, Germany  
ProSorb™, PVDF membrane Perkin Elmer, Foster City, CA, USA 
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3.2.     Methods 
3.2.1.    Purification of canine neutrophil elastase 
3.2.1.1.    Assay for proteolytic activity 
Fractions obtained at different stages of the purification procedure were screened for 
the presence of canine neutrophil elastase (cNE) activity by modification of a 
published spectrophotometric assay method (Nakajima et al., 1979). The assay was 
performed in 96-microwell plates. Briefly, 20 µl of a high ionic strength buffer (0.02 
M Tris, 1 M NaCl, 0.05% Tween, pH 8.5) were pipetted into each well, 50 µl of test 
sample were added, and the plate was incubated at room temperature for 5 minutes. 
After incubation 10 µl of methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide, a 
synthetic chromogenic substrate, were added to each well.  The plate was then placed 
immediately in an automated plate reader and the increase in absorbance was 
measured over a period of 15 min at 405 nm. 
One unit of enzyme activity was defined as the amount of material, which produced 
the equivalent activity of 1 µg of human neutrophil elastase under above assay 
conditions. 
 
3.2.1.2.    Preparation of neutrophils 
Blood was collected from healthy dogs euthanatized for unrelated research projects. 
Blood was drawn from the heart immediately following euthanasia. The blood was 
collected into 500 ml sterile nonpyrogenic evacuated blood collection bottles 
containing sodium citrate as an anticoagulant. The blood was immediately processed 
by mixing one volume of blood with 0.4 volume of a 60 mg/ml Dextran 500 solution, 
containing 9 mg/ml NaCl in a beaker. The mixture was stirred for 5 minutes and 
incubated at room temperature for 5 hours without stirring. During this period the 
erythrocytes settled to the bottom of the beaker. After the incubation time, two layers 
were clearly visible, a dark red layer on the bottom and a lighter layer on top. 
Preparation was continued with the top layer. The top layer was carefully aspirated 
and transferred in 50 ml polypropylene centrifugal tubes. The tubes were placed in a 
fixed angled rotor centrifuge and spun at 2,000 x g at 4ºC for 20 min. The supernatant 
was carefully discarded and the pellet was dissolved in a commercially available red 
blood cell lysis solution containing ammonium chloride, ethylenediaminetetraacetic 
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acid, and sodium bicarbonate (Gentra, Puregene® RBC Lysis solution). The dissolved 
pellet was incubated at room temperature for 20 minutes on a rocking plate. After the 
incubation time the tubes were placed into a fixed-angle centrifuge and spun at 2,000 
x g and 4ºC for 20 min. The obtained neutrophil rich pellet was stored at -20ºC until 
further use. 
 
3.2.1.3.    Extraction of neutrophil elastase 
The pellet was suspended in extraction buffer (20 ml 0.02 M Tris, 1 M NaCl, 0.05% 
Tween, pH 8.5). For full resuspension of the pellet a tissue grinder was used for 3 
minutes and the solution was subsequently vortexed for 2 minutes. The solution was 
afterwards frozen at -20ºC for 3 hours, thawed at room temperature, and ultra 
sonicated for 1.5 minutes at 50% power output. The freezing, thawing, sonication 
procedure was repeated three times.  Subsequently the solution was spun at 18,000 x g 
and 4ºC for 20 min. The pellet was discarded and the supernatant was filtered through 
a series of filters with decreasing pore size from 10 µm to a 0.8 µm and the buffer was 
exchanged to buffer A (0.05 M sodium acetate, 0.05 M NaCl, pH 5.0) for 12 hours, 
using dialysis tubing. After the initial exchange the dialysis buffer was exchanged two 
more times at 2 hour intervals.  
 
3.2.1.4.    Column chromatography - strong cation-exchange chromatography  
The filtered and dialyzed solution was loaded onto a 1.3 cm × 3.5 cm Macro-Prep® 
column. The column matrix consisted of spherical rigid polymers with sulphur ions as 
functional groups. The column had been previously equilibrated with buffer A. Ten 
ml of sample was loaded onto the column at a flow rate of 1 ml/min. Proteins not 
bound to the column were washed out with 5 column volumes of buffer A. Proteins 
that did not bind strongly to the column matrix were eluted using a step gradient of 
0.3 M NaCl in buffer A for 20 column volumes. More strongly bound proteins were 
eluted by a linear salt gradient ranging from 0.3 to 0.7 M NaCl in buffer A over 12 
column volumes  at a flow rate of 1 ml/min. Fractions of 3 ml each were collected. 
Fractions containing proteolytic activity against methoxysuccinyl-Ala-Ala-Pro-Val-p-
nitroanilide were pooled and concentrated using a centrifugal filter device with a 
molecular weight cut off of 10 kDa. The filter device was spun at 5,000 x g until the 
protein solution reached a concentration of approximately 0.6 - 0.7 mg/ml. 
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3.2.1.5.    Continuous-elution electrophoresis 
The concentrated protein solution obtained from the column chromatography step was 
further separated using the Bio-Rad Mini Prep Cell following the manufactures 
instructions. The acrylamide gel column was prepared 12 hours prior to the each run. 
Briefly, a stock solution of 30% acrylamide and bis (N, N’-bis-methylene-acrylamide) 
was prepared. From this stock solution 4.33 ml were mixed with 3.15 ml ultra pure 
water and 2.5 ml of 1.5 M Tris-HCl buffer, pH 8.8, to prepare a 13% resolving gel. 
Two ml of the resolving gel were blended with 5 µl of a 10% ammonium persulfate 
solution, 0.5 µl of tetra-methyl-ethylenediamine (TEMED), filled in a glass column 
and overlaid with iso-amyl alcohol. The acrylamide was allowed to polymerize for 12 
hours. One hour prior to each run, a second layer of acrylamide solution, the stacking 
gel, was applied. The 4% stacking gel consisted of 6.15 ml ddH20, 2.50 ml 0.5 M 
Tris-HCl buffer, pH 6.8, and 1.33 ml of 30% acrylamide/bis stock solution. Two ml 
of the stacking gel were mixed with 10 µl of a 10% ammonium persulfate solution, 2 
µl of TEMED, and were carefully layered on top of the resolving gel. After one hour 
of polymerization time 0.5 ml of sample were mixed with 0.5 ml sample buffer (0.06 
M Tris-HCl, 2% SDS, 5% beta mercaptoethanol, 25% glycerol (w/v) and 0.01% 
bromophenol blue, pH 6.8), incubated at 95°C for 4 min and loaded onto the gel 
column. The buffer reservoir of the Mini Prep Cell was filled with running buffer 
(0.025 M Tris-HCl, 0.192 M glycine, 0.1% SDS buffer, pH 8.3) and a constant 
voltage of 200 V was applied to the system. The proteins in the solution were 
separated according to their molecular weight and were discharged into the elution 
chamber at the bottom of the gel. From there the proteins were eluted in running 
buffer (0.025 M Tris, 0.192 M glycine, 0.1% SDS, pH 8.3) into different 300 µl 
fractions using a peristaltic pump. 
 
3.2.1.6.    Sodium-dodecyl-sulfate gel electrophorese (SDS-PAGE) 
The purity of the obtained protein was analyzed by sodium-dodecyl-sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. A pre-
cast, 1 mm thick 10% polyacrylamide gel was used. The gel cassette was tightly 
looked into the electrophoresis chamber, and the chamber was filled with MES 
running buffer (1 M 2-(N-morpholino) ethane sulfonic acid, 1 M Tris-base, 70 mM 
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SDS, 21 mM EDTA, pH 7.3). The samples were prepared by adding 24 µl of sample 
to 4 µl of reducing agent and 10 µl of NuPAGE® SDS sample buffer (4 g sucrose + 
0.68 g Tris-base + 0.67 g Tris-HCl + 0.8 g SDS + 0.006 g EDTA + 0.75 ml Serva 
blue G250 + 0.25 ml Phenol red + ultra pure water to 10 ml). Samples were incubated 
at 70°C for 10 min. After incubation 23 µl of each of the samples were loaded into the 
wells. In an addition to the samples a standard protein solution was loaded into the 
first lane. The standard protein solution contained 12 different proteins with a known 
molecular mass, including myosin: 200 kDa, β-galactosidase: 116.3 kDa, 
phosphorylase: 97.4 kDa, bovine serum albumin: 66.3 kDa, glutamic dehydrogenase: 
55.4 kDa, lactate dehydrogenase: 36.5 kDa, carbonic anhydrase: 31 kDa, trypsin 
inhibitor: 21.5 kDa, lysozyme: 14.4 kDa, aprotinin: 6 kDa, insulin B chain: 3.5 kDa, 
and insulin A chain: 2.5 kDa. The electrophoresis gel was run at a constant voltage of 
200 V for 35 minutes. Immediately after completion the gel was removed from the 
cassette and stained with a silver stain kit, according to the manufacture’s instructions. 
 
3.2.2.    Partial characterization of canine neutrophil elastase  
3.2.2.1.    Estimation of the molecular weight 
The molecular weight of canine neutrophil elastase was estimated by a chip based 
protein assay, performed on the Agilent 2100 bioanalyzer in combination with the 
Protein 50 Lab-Chip® kit. Data were analyzed with the Protein 50 assay software.  
The estimation of the molecular weight was based on the measured electrophoretic 
migration time of the protein given in seconds. The software automatically performed 
a sizing based on the alignment with internal makers and an external protein standard 
(ladder).   
In more details: The chip accommodates sample wells, gel wells and a well for an 
external standard (ladder). Micro-channels are fabricated in glass to create 
interconnected networks among these wells. During chip preparation, the micro-
channels are filled with a sieving polymer and fluorescence dye. Once the wells and 
channels are filled, the chip becomes an integrated electrical circuit. The 16-pin 
electrodes of the cartridge are arranged so that they fit into the wells of the chip. Each 
electrode is connected to an independent power supply. Proteins (charged 
biomolecules) are electrophoretically driven by a voltage gradient, similar to slab gel 
electrophoresis. Because of a constant mass-to-charge ratio and the presence of a 
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sieving polymer matrix, the molecules are separated by size (the smaller the protein 
the faster it migrates). Proteins are then intercalated with dye molecules and are 
detected by laser-induced fluorescence. Data is translated into gel-like images (bands) 
and electropherograms (peaks). A standard curve of migration time versus fragments 
size is plotted with the help of a ladder (protein standards). From the migration times 
measured for each fragment in the sample, the size is calculated. Two internal 
markers are run with each of the samples bracketing the overall sizing range. The 
“lower” and “upper” markers are internal standards used to align the ladder data with 
data from the sample wells. This is necessary to compensate for drift effects that may 
occur during the course of a chip run.  
Quantitation is done with the help of the upper marker. The area under the upper 
marker peak is compared with the sample peak areas. Because the concentration of 
the upper marker is known, the concentration for each sample can be calculated. 
The chip and the sample (purified cNE) were prepared according to the 
manufacturer’s instructions.  
 
 
3.2.2.2.    Estimation of isoelectric point 
The isoelectric point was estimated by polyacrylamide gel electrophoresis using a 
NOVEX® Pre-Cast vertical IEF gel, 5% polyacrylamide, and 2% ampholytes with a 
pH range of 3 to 10. Special protein markers for isoelectric focusing gels were used to 
generate a standard curve. The protein marker contained 9 different proteins, ranging 
from a pI 10.7 (cytochrome C, horse heart) to a pI 3.5 (amyloglucosidase, Aspergillus 
niger). 
The sample was prepared by thoroughly mixing one part of sample with one part of 
NOVEX® IEF sample buffer. The buffer for the cathode was prepared by adding one 
part NOVEX® IEF cathode buffer to nine parts of deionized water. The buffer was 
degassed for 20 minutes and then filled into the upper buffer chamber. The anode 
buffer was prepared by adding 1 part of NOVEX® IEF anode buffer to 49 parts of 
deionized water and poured into the lower buffer chamber. Samples were loaded into 
the wells and the gel was run at a constant voltage of 100 V for 1 hour, followed by a 
constant voltage of 200 V for 1 hour and finally at a constant voltage of 500 V for 30 
minutes. The gel was then removed from the cassette and incubated for 30 minutes in 
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fixing solution (17.3 g sulphosalicylic acid, 57.3 g trichloroacetic acid, in 500 ml 
deionized water). The gel was stained with a silver stain kit, following the 
manufacture’s instructions. A standard curve was generated by measuring the 
migration distance from the well to the protein bands of the markers. 
 
3.2.2.3.    Determination of the extinction coefficient for neutrophil elastase 
The extinction coefficient of cNE was determined based on the bicinchoninic acid 
(BCA) assay (Smith et al., 1985). The BCA™ protein assay is used for the 
colorimetric detection and quantification of total protein in a solution. The method is 
based on the reduction of Cu+2 to Cu+1 in an alkaline environment. The reduced 
copper forms a purple colored complex with bicinchoninic acid, which is 
colorimetrically measured at 542 nm. The absorbance of the complex is nearly 
proportional with increasing protein concentration. 
The assay was performed according to the manufacturer’s instructions in a microplate 
format. Briefly, 8 standards from bovine serum albumin were prepared. The protein 
concentration of the standards ranged from 2,000 µg/ml to 25 µg/ml. Purified cNE 
with a known absorbance at 280 nm was diluted 1 in 2, 1 in 4, and 1 in 8 in PBS. The 
BCA™ working reagent was prepared by mixing 50 parts of BCA™ reagent A 
(containing sodium carbonate, sodium bicarbonate, bicinchoninic acid, and sodium 
tartrate in 0.1 M sodium hydroxide) with 1 part of BCA™ reagent B (4% cupric 
sulfate). A volume of 15 µl of each standard, samples, and a blank was loaded into the 
microplate wells, and 200 µl of the previously mixed BCA™ working reagent were 
added to each well. The plate was incubated for 30 min at 37ºC, and the absorbance 
was measured at 562 nm. 
The absorbance of each well was corrected for non-specific binding (blank). A 
standard curve was prepared by plotting the average of the duplicates for each BSA 
standard versus its concentration in µg/ml. The protein concentration of each 
unknown sample was interpolated from the standard curve  
The extinction coefficient was calculated by dividing the previously measured 
absorbance of the pure protein solution at 280 nm by the protein concentration, 
calculated with the help of the BCA™ protein assay. Each of the 3 cNE dilutions (1 in 
2, 1 in 4, and 1 in 8) were calculated and the mean was taken. 
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3.2.2.4.    Material preparation for N-terminal amino acid sequencing  
Twenty µg of purified cNE were transferred onto a PVDF membrane using the 
ProSorb™ sample preparation cartridge. The protein transfer was done according to 
the manufacture's protocol. The sample was analyzed at the Department of 
Biotechnology at the Jagiellonian University and Bio Centrum Ltd. facility in 
Kraków, Poland. The N-terminal amino acid sequence analysis of the first 25 residues 
of canine neutrophil elastase was obtained by use of the Edman degradation method. 
During the Edman degradation method phenylisothiocyanate reacts with the amino 
acid residue at the amino terminus to form a phenylthiocarbamoyl derivative. 
Trifluoroacetic acid is used to cleave off the first amino acid as its anilinothialinone 
derivative, followed by the conversion to a phenylthiohydantoin derivative. Bound to 
phenylthiohydantoin the amino acid is then detected by high-performance liquid 
chromatography (HPLC). This process was repeated sequentially until the first 25 
amino acid residues were determined. 
 
3.2.3.    Production of anti-canine neutrophil elastase antiserum   
A single rabbit (Oryctolagus cuniculus) was vaccinated with 200 µg of cNE mixed 
with 0.5 ml complete Freund’s adjuvant. For reinoculations 150 µg cNE mixed with 
0.5 ml incomplete Freund’s adjuvant were administered on days 21, 42, and 63. Sera 
were collected by venipuncture of the ear vein, before each booster vaccination. After 
a total of 4 vaccinations the rabbit was exsanguinated.  
 
3.2.3.1.    Determination of antibody titer  
To estimate the antibody concentration in the serum of the rabbit, an indirect ELISA 
was performed. A 96-microwell plate was coated with 500 ng/well of pure cNE in 
100 µl/well carbonate-bicarbonate buffer, pH 9.4, and incubated at 37°C in a plate 
shaker for 1 hour. The plate was washed 4 times with 200 µl/well of PBS, pH 7.2. 
Remaining binding sites were blocked with 200 µl/well of 1% bovine serum albumin 
(BSA) in PBS. The plate was again incubated for 1 hour at 37ºC and washed as 
described above. The antiserum to be tested was diluted 1 in 100 in PBS +1% BSA 
+0.05% polyoxy-ethylene sorbitan monolaurate (Tween), followed by a dilution 
series of 1 in 2, with a final dilution of  1 in 204,800.  
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A volume of 100 µl/well of the serum dilutions were loaded in duplicates. As a 
negative control 100 µl of PBS +1% BSA +0.05% Tween (PBS+BSA+Tween) was 
used. The plate was incubated for 1 hour at 37ºC and washed as described above. A 
solution containing 100 ng of anti-rabbit antibodies coupled to horseradish peroxidase 
in 100 µl of PBS+BSA+Tween was added to each well. After incubation for 1 hour at 
37ºC and washing as described the retained horseradish peroxidase was visualized by 
adding 100 µl/well 3,3’,5,5’-tetramethylbenzidine solution. The reaction was stopped 
after 2 minutes by adding 100 µl/well of stopping solution (4 M acetic acid, 1 N 
sulfuric acid). The absorbance was read at a wavelength of 450 nm in an automated 
plate reader.   
 
3.2.3.2.    Ouchterlony double immunodiffusion assay 
The cross reactivity of human neutrophil elastase with cNE antiserum was evaluated 
by an Ouchterlony double immunodiffusion assay. The assay is based on the principle 
that macromolecular antigens and antibodies form complexes that become insoluble 
and precipitate. Canine NE antiserum, produced as described above, purified cNE and 
commercially available human neutrophil elastase were used for this procedure. A 
volume of 23 µl of each material, as well as a blank (PBS) were placed in separate 
wells cut in an agarose plate. The plate was incubated at 37ºC for 12 hours in a moist 
environment, to prevent the plate from drying out. After the incubation time the plate 
was examined for precipitation lines. 
 
3.2.4.    Purification of anti-canine neutrophil elastase antibodies 
3.2.4.1.    Preparation of affinity chromatography column  
Monospecific polyclonal antibodies were purified by the use of an affinity 
chromatography column. The column was prepared following the manufacturer’s 
instruction. Briefly, 0.7 mg of cNE was buffer exchanged against a ligand buffer (200 
mM NaHCO3, 500 mM NaCl, pH 8.3) using a PD-10 disposable gel filtration column. 
The PD-10 column was equilibrated with 30 ml of ligand buffer. Two and a half ml of 
protein solution were applied onto the column and the effluent discarded. Then 3.5 ml 
of ligand buffer were applied onto the column and the effluent was collected. The 
ligand solution (0.7 mg of NE in ligand buffer) was concentrated to a volume of 1 ml 
using a centrifugal filtration device. 
MATERIALS AND METHODS 
 28 
Before ligation the affinity column was washed with 3 bed volumes (6 ml) of ice-cold 
1 mM HCl at a flow rate of ½ drop per second. The ligand solution was then slowly 
applied and the column was incubated for 1 hour at room temperature. The column 
was washed with 6 ml 500 mM ethanolamine, 500 mM NaCl, pH 8.3 (buffer I), 
followed by 6 ml 100 mM sodium acetate, 500 mM NaCl, pH 4.0 (buffer II), followed 
by 6 ml of buffer I. The column was incubated for 30 min at room temperature and 
then washed with 6 ml buffer II, 6 ml buffer I, and 6 ml buffer II. After this the 
column was equilibrated with 75 mM Tris-HCl, 150 mM NaCl buffer, pH 8.0 and 
stored until further use. 
 
3.2.4.2.     Affinity chromatography of anti-canine neutrophil elastase antibodies 
The rabbit antiserum was prepared for purification by lipoprotein precipitation. 
Briefly, 20 ml of rabbit antiserum were thawed and added to 20 ml of 1 M CaCl2 and 
800 µl of 10% dextran sulfate solution. The mixture was gently mixed in a 50 ml 
centrifuge tube on a plate rocker for 20 minutes at 4ºC and subsequently centrifuged 
at 10,000 × g and 4ºC for 10 minutes. The precipitate was discarded and the 
supernatant was filtered through a filter paper. A PD-10 disposable gel filtration 
column was used for buffer exchange to 75 mM Tris-HCl, 150 mM NaCl, pH 8.0 
(buffer III), following the manufacturer’s instructions.  
The previously prepared affinity column was attached to a fast performance liquid 
chromatography (FPLC) purification system and equilibrated with buffer III. Two ml 
of the buffer exchanged antibody solution were applied onto the column. The 
absorbance of the effluent was measured at a wavelength of 280 nm. The column was 
washed with buffer III until the absorbance had returned to baseline, then the mobile 
phase was changed to 100 mM glycine, 500 mM NaCl, pH 2 (buffer IV), and 1 ml 
fractions of the effluent were collected in test tubes containing 300 µl of 1 M Tris-
HCl, pH 8.0. The eluting peak was collected and all fractions belonging to that peak 
were pooled, concentrated, and buffer exchanged to PBS, pH 7.2 using a centrifugal 
filter device. The antibody concentration was adjusted to 1 mg/ml, and aliquots of 250 
µl were stored frozen at -20ºC until further use.  
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3.2.4.3.    Biotinylation of purified antibodies 
For biotinylation, 0.7 mg of the purified monospecific polyclonal cNE-antibody in 
PBS, pH 7.2, were mixed with a 20-fold molar excess of biotin. After incubation for 
45 min at room temperature, the material was immediately buffer exchanged against 
PBS, pH 7.2. For this procedure a disposable centrifugal filter device was used. The 
filter was filled with the antibody-biotin mixture, spun at 6,000 x g for 20 min at 4ºC, 
refilled with PBS and spun another time at 6,000 x g. This procedure war repeated 5 
times.  
Biotinylation efficiency was determined by use of a 2-4’-hydroxyazonbenzene 
benzoic acid avidin assay kit. Briefly, 24.2 mg of HABA were mixed with 9.9 ml of 
ultra pure water and 200 µl of 1 N NaOH were added. The solution was filtered 
through a 0.45 µm pore-size syringe filter to remove solids. Then 500 µl of a 1 mg/ml 
avidin solution were mixed with 470 µl PBS and 30 µl HABA solution. The 
absorbance was measured at a wavelength of 500 nm. Then 50 µl were removed from 
the avidin/PBS/HABA solution and replaced by 50 µl of biotinylated antibodies. The 
absorbance was again measured at 500 nm. The procedure was repeated until a 
biotinylation coefficient of between 3.0 and 4.0 was reached. The biotinylated 
antibodies were adjusted to a concentration of 1 mg/ml and frozen in aliquots of 100 
µl at -20ºC until further use. 
 
3.2.5.   Set-up of an enzyme linked immunoassay (ELISA) for the measurement 
of canine neutrophil elastase concentration in serum 
Standard 96-well flat-bottom ELISA plates were coated with 200 ng/well affinity 
purified anti-cNE antibodies in 100 µl of carbonate-bicarbonate buffer, pH 9.4. Plates 
were mixed using a plate vortexer and incubated for 1 hour at 37ºC using an 
automated plate incubator/shaker and then washed 4 times with 200 µl/well of 50 mM 
Tris-base buffer, containing 0.14 M NaCl, pH 7.2 (TBS). Remaining binding sites 
were blocked with 200 µl/well of 10% bovine serum albumin (BSA) in PBS. Plates 
were again incubated for 1 hour at 37ºC and washed as described above. Standard 
solutions of cNE were prepared by serial dilution of pure canine neutrophil elastase in 
TBS, 1% BSA, and 0.05% Tween (TBS+BSA+Tween). Standards of 640, 320, 160, 
80, 40, 20, 10, 5, 2.5, 1.25 and 0.63 µg/L cNE were prepared and frozen at –80ºC in 
aliquots of 300 µl each. The standard solutions were thawed immediately prior to 
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loading the plate. Control and unknown samples were prepared in a 1 in 20 dilution 
with buffer A. Standards, negative control, and diluted samples were loaded in 
duplicates (100 µl/well). As a negative control 100 µl of TBS+BSA+Tween were 
used. Plates were incubated for 3 hours at 37ºC and washed as described above. A 
solution containing 100 ng of biotinylated anti-cNE antibodies in 100 µl of 
PBS+BSA+Tween was added to each well. After incubation for 1 hour at 37ºC and 
washing as described above, 8 ng/well of horseradish peroxidase-labeled streptavidin 
in 100 µl TBS+BSA+Tween was added to each well. Plates were once again 
incubated for 1 hour at 37ºC and washed as above. Retained horseradish peroxidase 
was developed by adding 100 µl/well 3, 3’, 5, 5’-tetramethylbenzidine solution. The 
reaction was stopped after 20 minutes by adding 100 µl/well stopping solution (4 M 
acetic acid, 1 N sulfuric acid). Absorbance was read at a wavelength of 450 nm using 
an automated plate reader.  
Standard curves were calculated by a 4-parameter curve fit using the mathematical 
equation: y=([A-D]/[1+(x/C)B])+D, where D is the y-value corresponding to the 
asymptote of the x-axis at high values, A is the y-value corresponding to the 
asymptote of the x-axis at low values, C is the x-value corresponding to the midpoint 
between A and D, and B describes how rapidly the curve makes the transition from 
the asymptotes in the center of the curve. All four parameters were calculated by use 
of an algorithm based on the Levenberg-Marquardt equation. 
 
3.2.5.1.   Validation of the ELISA 
The ELISA was validated by determination of assay sensitivity, upper limit of the 
working range, dilutional parallelism, spiking recovery, intra-assay variability, and 
inter-assay variability.  
The assay detection limit (sensitivity) was defined as the apparent concentration of 
cNE that produces an absorbance equal to the mean plus 3 times the standard 
deviation of the absorbance of 10 duplicates of a negative control solution 
(PBS+BSA+Tween).  
The upper limit of the working range was defined as the apparent concentration of 
cNE that produces an absorbance equal to the mean minus 3 times the standard 
deviation of the absorbance of 10 duplicates of a cNE solution of 2,000 µg/L.  
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Four different serum samples were used to determine dilutional parallelism. The 
samples were evaluated at dilutions of 1 in 10, 1 in 20, 1 in 40, and 1 in 80.  
Spiking recovery was determined by adding 640, 320, 160, 80, 40, 20, and 10 µg/L 
cNE to 4 different serum samples.  
Intra-assay variability was determined by evaluating 4 different serum samples 10 
times in duplicates within the same assay run.  
Inter-assay variability was determined by evaluating 4 different serum samples during 
10 consecutive assay runs. 
 
3.2.6. Serum canine neutrophil elastase concentration in healthy dogs 
A total number of 54 serum samples from clinically healthy dogs were collected. The 
dogs were owned by students or staff of the Texas A&M University. The drawing of 
blood was approved by the Clinical Research Review Committee of the Texas 
Veterinary Medical Center at Texas A&M University. All dogs underwent a short 
physical examination. Also, trypsin-like immunoreactivity (TLI), canine pancreatic-
lipase immunoreactivity (cPLI), cobalamin, folate and C-reactive protein (CRP) were 
measured and had to be within the normal range for the dog to be included in this 
healthy control group. 
The data were analyzed by determining the mean and standard deviation. The 
reference range was calculated using the lower 95th percentile. 
 
3.2.7.  Serum canine neutrophil elastase concentration in dogs with 
gastrointestinal disease 
Ninety seven dogs were enrolled in this study. Fifty six of these diseased dogs were 
referred to a veterinary referral center in Denmark, specialized in gastrointestinal 
diseases. There they underwent endoscopy and intestinal biopsies were taken. 
Biopsies were evaluated by specialized veterinary pathologists. The diagnosis was 
based on the histopathologic results. The remaining 41 dogs enrolled in this study 
were submitted to the GI lab at Texas A&M University and had cPLI concentrations 
diagnostic for pancreatitis. 
The dogs were organized in 4 groups, based on the histopathologic results of their 
biopsies or their cPLI concentration. Group 1 contained dogs with lymphocytic-
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plasmacytic enteritis, group 2 included dogs with eosinophilic enteritis, group 3 
consisted of dogs with the diagnosis of gastritis, and group 4 included dogs diagnosed 
with pancreatitis based on their serum cPLI concentration. 
Serum cNE was measured by ELISA in all 97 dogs. Data were analyzed using a 
statistical software package using the Kruskal-Wallis test for nonparametric 
comparison with the Dunn’s post test for multiple comparisons. Statistical 
significance was assigned for values of p < 0.05. 
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4.    RESULTS 
4.1.    Purification of Neutrophil Elastase (NE) 
For measurement of NE activity a specific substrate for NE was used. Figure 1 shows 
typical results of this activity assay for solutions containing various NE activities. 
Intracellular proteins were extracted from neutrophils. Briefly, after 5 hours of 
incubation, the blood-dextran solution formed 2 layers. The erythrocytes settled to the 
bottom of the beaker forming a dark red layer, while the top layer had a milky 
appearance. After centrifugation of the top layer, a white opaque pellet with some 
contaminating erythrocytes was harvested. Following treatment with a hypotonic 
solution and centrifugation, a pellet free off contaminating red blood cells was 
obtained. 
The extraction of NE from the neutrophil rich pellets resulted in an opaque solution 
that was further purified by strong cation-exchange chromatography (see Figure 2 for 
a typical chromatogram). Significant purification of cNE was obtained during this 
chromatography step.  
Figure 3 shows a NuPAGE SDS gel of fractions showing high NE activity during the 
enzymatic assay after separation by strong cation-exchange chromatography. The two 
protein bands visible on the gel in figure 3 were successfully separated using 
continuous-elution electrophoresis on a Mini Prep Cell®. Figure 4 shows pure cNE on 
a NuPAGE SDS gel after continuous-elution electrophoresis. 
Figure 5 shows a test run with prestained molecular weight standards to visualize the 
separation of a protein mixture into individual bands using continuous-elution 
electrophoresis. Figure 6 displays the different purity stages of the protein solution 
during the purification of cNE. Table 3 summarizes the major steps involved in the 
purification of canine neutrophil elastase from 0.3 liter of blood. Percent of recovery 
and degree of purification are given for each step. Several different preparative runs 
gave essentially similar results to those shown in table 3. 
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Figure 1: Activity assay for the measurement of NE activity. The assay was 
performed using methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide as a NE-specific 
substrate. A 96-microwell format was used and the increase in absorbance was 
measured over 15 min at a wavelength of 405 nm using an automated plate reader. 
Samples were analyzed in duplicate fashion. Panel A graphically displays the increase 
in absorbance over 15 minutes in 16 different wells arranged in two columns. Panel B 
shows numerical values for the changes in absorbance displayed in panel A. Wells A1 
and A2 are negative controls (blank), B1 and B2 are positive controls, and C1 and C2 
to H1 and H2 show the results for unknown samples. The absorbance of the blank is 
close to zero indicating that no NE is present in the well. The positive control consists 
of a solution of 5 µg/ml human NE in 0.02 M Tris, 1 M NaCl, 0.05% Tween, pH 8.5 
and shows an increase in absorbance over time indicated by the positive number. The 
samples in this run contain various amounts of NE activity. 
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Figure 2: Strong cation-exchange chromatography  
This figure shows a typical chromatogram of strong cation-exchange chromatography of a canine neutrophil extract. Absorbance at 280 nm is 
displayed on the y-axis on the left. The extract separated into four distinct peaks (I-IV). Peak I represents proteins that did not interact with the 
column matrix and were washed out immediately. Peak II represents proteins that bound only weakly to the column and were washed out with a 
low ionic strength buffer. Both peaks (I and II) had little enzymatic activity. The red y-axis on the right displays the enzymatic activity of each 
fraction as measured by the activity assay described. The main NE activity was found in the fractions of the descending slope of peak III. Peak 
IV consisted of proteins that were strongly bound to the column. Fractions with NE activity were eluted from the column with a salt 
concentration between 0.4 and 0.7 M NaCl. 
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Figure 3: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
after strong-cation exchange chromatography.  
SDS-PAGE was performed under reducing conditions on a 1 mm thick, 10% Bis-Tris 
gel. The numbers and bands on the left of the figure display molecular mass 
standards. All nine wells of the gel were loaded with various fractions within peak III. 
All fractions showed a high enzymatic activity. These fractions were concentrated and 
loaded onto the Mini Prep Cell® for further purification. Clear bands are visible in the 
molecular mass range reported for NE. 
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Figure 4: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) after continuous elution electrophoresis on the Mini Prep Cell
®
. 
The figure shows a single protein band per lane. These bands represents purified cNE 
after continuous elution electrophoresis on the Mini Prep Cell®. Four consecutively 
eluting fractions were loaded onto the gel. SDS-PAGE was run under reducing 
conditions on a 1 mm thick, 10% Bis-Tris gel. The numbers and bands on the left of 
the figure, display molecular mass standards.    
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Figure 5: Continuous-elution electrophoresis on a Mini Prep Cell
®
. 
This picture shows the acrylamide gel column in the center of the Mini Prep Cell® 
used for continuous gel electrophoresis. In this particular run prestained molecular 
mass standards were loaded in order to visualize the separation of a protein mixture 
into individual bands during their migration through the acrylamide gel column. The 
prestained molecular mass standards consisted of 10 different proteins: myosin (250 
kDa), BSA (98 kDa), glutamic dehydrogenase (64 kDa), alcohol dehydrogenase (50 
kDa), carbonic anhydrase (36 kDa), myoglobin (30 kDa), lysozyme (16 kDa), 
aprotinin (6 kDa), and insulin B chain (4 kDa). 
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Figure 6: Different purity stages of cNE visualized by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE).  
This figure shows photographs of three different SDS-PAGE gels. Each SDS-PAGE 
gel was run under reducing conditions on a 1 mm thick 10% Bis-Tris gel. The 
numbers and bands on the left of the figure, display molecular mass standards.   Lanes 
in panel A show the banding pattern of the neutrophil extract. Lanes in panel B show 
the banding pattern after cation-exchange chromatography. Lanes in panel C show a 
single band representing pure canine NE after continuous elution electrophoresis. 
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Table 3: Sequential purification of cNE from 0.3 L of whole blood.  
This table summarizes the total amount of protein in mg, the total elastase activity, the 
specific elastase activity, and the yield after each purification step starting with 0.3 L 
of whole blood. The recovery was calculated based on the total activity. 
 
 
 
 
Purification Stage 
 
Total 
Protein  
(mg*) 
 
Total 
Activity 
(AU**) 
Specific 
Activity 
(AU/mg of 
protein) 
 
Yield   
(%) 
 
Neutrophil preparation 
 
 
1,100 
 
186 
 
0.17 
 
100.0 
 
Neutrophil extract 
  
 
220 
 
306 
 
1.39 
 
164.5 
 
Post strong cation-
exchange 
chromatography 
 
 
1.6 
 
34 
 
21.25 
 
18.3 
 
Post continuous elution 
electrophoresis 
 
 
0.6 
 
17 
 
28.33 
 
9.14 
 
* The amount of total protein is based on the absorbance at 280 nm. 
 
** One activity unit (AU) is defined as an increase of absorbance in the     
methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide activity assay at 405 nm over 15 
min multiplied by 1,000. 
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4.2.    Partial characterization of cNE 
The molecular mass of cNE as determined by the Agilent 2100 bioanalyzer in 
combination with the Protein 50 Lab-Chip® kit was found to be 26,500 Dalton 
(figures 7 and 8, table 4). The IEF gel showed an isoelectric point (pI) for cNE 
between 8.5 and 9.0 (figure 9). 
The extinction coefficient of cNE as determined by bicinchoninic acid (BCA) assay 
was 0.85 for a 1 mg/ml solution (table 5). 
Table 6 shows the first 25 amino acid sequence of NE in different species. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Electropherogram of the analysis of cNE on the Agilent 2100 
bioanalyzer. 
This figure shows the fluorescence intensity plotted versus size/migration time. Peak I 
(26.9 s) represents the lower molecular mass marker with a size of 3.5 kDa, peaks II 
and III (28.35 s and 29.35 s) are system peaks (used for internal calibration), and peak 
V (47.55 s) represents the upper molecular mass marker with a size of 53.0 kDa. The 
lower and upper molecular mass markers are internal standards used to align the 
ladder data with the data from the sample wells. Peak IV represents cNE at a 
migration time of 39.6 s. 
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Table 4: Molecular mass of cNE.  
The molecular mass of each protein was calculated by interpolation from a standard 
curve, which was generated by plotting migration time of the protein versus the 
molecular mass from data generated with the Agilent 2100 bioanalyzer. The 
molecular mass of cNE was determined to be 26.5 kDa. 
The concentration of the protein was calculated by comparison of the area under the 
curve of the upper molecular mass marker with the area under the curve of the 
sample. The concentration for cNE in the sample analyzed is 414.5 µg/L. 
(N/A= not applicable) 
 
 
 
Peak   Migration Time     Corrected       Size       Relative Conc.    Total             Observations  
                    (in s)                 Area          (kDa)          (µg/ml)               %                   Marker 
           
  1    26.90  147.01           3.5    N/A            N/A             Lower marker 
  2    28.35    16.67           4.1    N/A            N/A      System peak      
  3    29.35  408.10           4.6    N/A            N/A      System peak      
  4    39.60  128.01         26.5  414.5          100.0                N/A            
  5    47.55    30.88         53.0  100.0            N/A                    Upper marker 
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Figure 8: Molecular mass of cNE.  
This figure shows and SDS gel-like image obtained from the Agilent 2100 
bioanalyzer. The ladder on the left side of the gel contains markers of known size. 
Lanes 1-5 contain different samples of pure cNE. In each lane, cNE, the upper and 
lower markers, as well as the system peak are visible.  
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Figure 9: Isoelectric focusing of cNE. 
The left side of this figure displays the isoelectric points of the marker bands. The 
marker bands are proteins with known isoelectric points, including ribonuclease A (pI 
9.5), lectin (pI 8.0), carbonic anhydrase (pI 6.0), β-lactoglobulin (pI 5.3 and 5.2), 
trypsin inhibitor (pI 4.5), glucose oxidase (pI 4.2), and amyloglucosidase (pI 3.5). On 
the right side, cNE results in a band in the pI range of pI 8.5-9.0. 
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Table 5: BCA assay. 
This table shows the results of a BCA assay. The absorption of pure cNE in PBS, pH 
7.2 at a wavelength of 280 nm (A280) was 0.225. The concentration of this solution 
was measured in the BCA assay at dilutions of 1 in 2, 1 in 4, and 1 in 8. PBS, pH 7.2 
was used as diluent. The mean of the three dilutions was calculated, and the specific 
absorbance of cNE at 280 nm was determined to be 0.85 for a 1 mg/ml solution. 
 
 
 
Dilution factor 
 
A280 
 
Protein 
concentration 
(µg/ml) 
 
Extinction 
coefficient 
    
2 0.1125 126.95 0.89 
4 0.0563 66.04 0.85 
8 0.0281 34.62 0.81 
Mean   0.85 
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 Table 6: Amino acid sequence of the first 25 N-terminal amino acids of cNE compared to the amino acid sequence of NE from 3 other species. 
This table shows the amino acid sequence of the first 25 N-terminal amino acids of dog, rat, mouse, and human NE. Compared to cNE, rat NE shows 100% 
homology, mouse NE shows 96% homology, and human NE shows 92% homology. The amino acids in the rat, mouse, and human sequence that are different 
from the one in the canine sequence are bold and in red. 
 
 
Dog I V G G R P A Q P H A W P F M V S L Q R R G G H F   
Rat I V G G R P A Q P H A W P F M V S L Q R R G G H F 100% 
Mouse I V G G R P A R P H A W P F M V S L Q R R G G H F 96% 
Human I V G G R R A R P H A W P F M V S L Q L R G G H F 92% 
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4.3.    Production of anti-canine neutrophil elastase antibodies 
A single rabbit (Oryctolagus cuniculus) was vaccinated with an initial dose of 200 µg 
of cNE on day 1, followed by 150 µg of cNE on days 21, 42, and 63. The antibody 
titer was evaluated by an indirect ELISA (Figure 10). An increase in binding over a  
period of the 4 vaccinations with cNE was observed.  
There was no immuno cross-reactivity between human NE and the cNE antiserum, as 
tested by an Ouchterlony double immunodiffusion assay. 
For the development and validation of the cNE-specific ELISA, monospecific 
polyclonal anti-cNE antibodies were purified by affinity chromatography. Figure 11 
shows a typical chromatogram of the affinity purification of anti-cNE antibodies. The 
specific yield for antibody purification was 0.1 mg of anti-cNE IgG per 1 ml 
antiserum. A total of 3.2 mg of anti-cNE antibody was purified. A total of 0.8 mg of 
anti-cNE antibodies were biotinylated for use as the reporter antibody in the ELISA. 
Use of a 20-fold molar excess of biotin and incubation for 1 hour and 20 minutes at 
room temperature led to a biotinylation coefficient of 2.7. 
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Figure 10: Antibody titer against cNE.  
This figure shows the serum anti-cNE antibody titer in a rabbit after the 2nd, 3rd, and 
4th vaccination measured by indirect ELISA. The rabbit was initially vaccinated with 
200 µg cNE in PBS (1st vaccination) and subsequently with 150 µg cNE in PBS (2nd - 
4th vaccinations). A volume of 0.5 ml of incomplete Freund’s adjuvant was added to 
each vaccination. An increase in binding from the 2nd vaccination (gray solid line) to 
the 4th vaccination (black solid line) is apparent. The serum was also tested for anti-
cNE antibodies prior to the first vaccination and showed no binding (pre-bleed, gray 
dashed line). 
The figure displays the absorbance at 450 nm, as measured by an indirect ELISA, at 
different antiserum dilutions starting at 1/100 (labeled 100) down to 1/820,200 
(labeled 820,200). 
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Figure 11: Affinity chromatography of anti-cNE antiserum.  
Purification of anti-cNE monospecific polyclonal antibodies by affinity 
chromatography. The column was equilibrated with 75 mM Tris HCl, 150 mM NaCl, 
pH 8.0 and 2 ml of rabbit serum was applied onto the column. Absorbance at 280 nm 
is shown on the y-axis on the left side. There are two distinct peaks (solid black line). 
Peak I represents proteins that did not bind to the column and were washed out 
immediately. Peak II represents anti-cNE monospecific polyclonal antibodies that 
bound to the affinity column and were then eluted with 100% buffer B (100 mM 
glycine, 500 mM NaCl, pH 2.0; dotted gray line).  
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4.4.    Development and validation of an ELISA for the measurement of cNE 
concentration in serum 
The ELISA protocol described resulted in reproducible standard curves, with 
standards ranging from 10 µg/L to 1,280 µg/L (Figure 12).  
The mean (±SD) absorbance at 450 nm of 10 duplicate samples of a negative control 
sample (blank: 50 mM TBS, 1% BSA, 0.05% Tween-20, pH 8.0) was 0.156 
(±0.0154). Extrapolation from the standard curve for an absorbance of the mean plus 
three times the SD was equivalent to a cNE concentration of 55 µg/L. Because serum 
samples were diluted 1:20 prior to running the assay, this resulted in a calculated 
assay sensitivity of 1,100 µg/L for serum samples. Mean (±SD) absorbance at 450 nm 
of 10 duplicate samples containing 2,000 µg of cNE per liter was 1.181 (±0.050). 
Extrapolation from the standard curve for an absorbance of the mean minus three 
times the SD was equivalent to a cNE concentration of 2075 µg/L. As for the 
sensitivity, since serum samples were diluted 1:20 prior to running the assay the 
corresponding maximum in serum was 41,500 µg/L.  
Linearity of the assay was determined by evaluating dilutional parallelism. Ratios of 
observed to expected results for 4 different serum samples and 4 dilutions ranged 
from 85.4 to 123.1% with a mean (±SD) of  101.7% (±14.9%; Table 7).  
Accuracy of the assay was evaluated by determining spiking recovery. Ratios of 
observed to expected results for 4 different serum samples and 7 different spiking 
concentrations ranged from 27.1 to 114.0% with a mean (±SD) of 93.0% (±15.45%; 
Table 8). 
Intra-assay variability for 4 different serum samples ranged from 13.4 to 16.8% with a 
mean (±SD) of 15.1% (±1.6%; Table 9).  
Inter-assay variability for 4 different serum samples ranged from 10.5 to 15.4% with a 
mean (±SD) of 13.9% (±2.3%; Table 10). 
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Figure 12: Standard curve for the cNE ELISA.  
This figure shows a typical standard curve for the cNE ELISA. Standard 
concentrations ranged from 10 to 1280 µg/L. The curve was calculated by the use of a 
computer software package using a 4-parameter curve fit. All four parameters were 
calculated by use of an algorithm based on the Levenberg-Marquardt equation. 
cNE concentration µg/L 
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Table 7: Dilutional parallelism for the cNE ELISA. 
Dilutional parallelism for 4 different serum samples. Samples were diluted in TBS, 
1% BSA, 0.05% Tween-20, pH 8.0. All samples were evaluated in a duplicate 
fashion. (O/E = (observed / expected)*100; N/A = not applicable). 
 
 
 
 
 
 
Sample  Dilution  Observed (µg/L) Expected (µg/L) O/E (%) 
          
1 1 in 10 3458.8 N/A N/A 
  1 in 20 2114.2 1729.4 122.3 
  1 in 40 756.4 864.7 87.5 
  1 in 80 370.7 432.4 85.7 
          
2 1 in 10 7788.5 N/A N/A 
  1 in 20 4794.8 3894.3 123.1 
  1 in 40 2350.9 1947.1 120.7 
  1 in 80 963.8 973.6 99.0 
          
3 1 in 10 29883.9 N/A N/A 
  1 in 20 12758.3 14941.9 85.4 
  1 in 40 7176.5 7470.9 96.1 
  1 in 80 3233.3 3735.5 86.6 
          
4 1 in 10 4203.5 N/A N/A 
  1 in 20 2426.0 2101.8 115.4 
  1 in 40 1059.7 1050.9 100.8 
  1 in 80 513.2 525.4 97.7 
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Table 8: Spiking recovery for cNE ELISA.  
Spiking recovery was determined by adding 10, 20, 40, 80, 160, 320, and 640 µg/L 
cNE to aliquots of 4 different serum samples. The recovery of the spiked cNE ranged 
from 27.1% to 114.0% (O/E = (observed / expected)*100; N/A = not applicable). 
 
 
 
Sample 
Spiking conc. 
added 
Observed 
(µg/L) 
Expected 
(µg/L) % O/E 
     
1 0.0 54.8 N/A N/A 
 10.0 52.9 64.8 81.7 
 20.0 73.6 74.8 98.4 
 40.0 78.1 94.8 82.5 
 80.0 130.2 134.8 96.6 
 160.0 230.5 214.8 107.3 
 320.0 390.5 374.8 104.2 
 640.0 639.4 694.8 92.0 
     
2 0.0 197.2 N/A N/A 
 10.0 182.2 207.2 87.9 
 20.0 190.4 217.2 87.6 
 40.0 209.8 237.2 88.4 
 80.0 236.9 277.2 85.4 
 160.0 311.9 357.2 87.3 
 320.0 497.5 517.2 96.2 
 640.0 702.3 837.2 83.9 
     
3 0.0 307.4 N/A N/A 
 10.0 328.4 317.4 103.5 
 20.0 373.1 327.4 114.0 
 40.0 325.1 347.4 93.6 
 80.0 378.2 387.4 97.6 
 160.0 467.5 467.4 100.0 
 320.0 601.9 627.4 95.9 
 640.0 992.2 947.4 104.7 
     
4 0.0 60.2 N/A N/A 
 10.0 72.1 70.2 102.7 
 20.0 21.8 80.2 27.1 
 40.0 110.1 100.2 109.9 
 80.0 138.2 140.2 98.6 
 160.0 203.7 220.2 92.5 
 320.0 328.1 380.2 86.3 
 640.0 589.9 700.2 84.3 
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Table 9: Intra-assay variability for the cNE ELISA. 
This table shows the intra-assay variability for the cNE ELISA. Four different serum 
samples were assayed 10 times during the same assay run. All samples were evaluated 
in duplicates. The results displayed have been multiplied by 20 to reflect true serum 
concentrations. The variability ranged from 13.4 to 16.8% with a mean (±SD) of 
15.1% (±1.6%).  
 (SD = standard deviation; %CV = coefficient of variation; %CV = (SD/mean)*100).  
 
 
 
 
 
 
 
 
 
 
 
sample Mean (µg/L)  SD (µg/L)  %CV 
      
1 5568.1  791.0  14.2 
      
2 5312.2  891.7  16.0 
      
3 19171.0  3073.7  16.8 
      
4 3363.8  451.6  13.4 
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Table 10: Inter-assay variation for cNE ELISA. 
This table shows the inter-assay variability for the cNE ELISA. Four different serum 
samples were assayed 10 times during consecutive assay runs. All samples were 
evaluated in duplicate fashion. The results displayed have been multiplied by 20 to 
reflect true serum concentrations. The inter-assay variability ranged from 10.5 to 
15.4% with a mean (±SD) of 13.9% (±2.3%). 
 (SD = standard deviation; CV = coefficient of variation; CV = (SD/mean)*100). 
 
 
 
 
 
 
 
 
 
 
 
 
sample Mean (µg/L)   SD (µg/L)    CV (%) 
            
1 4882.2  753.9  15.4 
      
2 8764.4  1315.4  15.0 
      
3 25073.2  2641.5  10.5 
      
4 4056.8  592.9  14.6 
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4.5. Serum canine neutrophil elastase concentrations in healthy dogs  
Serum cNE concentrations were measured in 54 healthy dogs. The dogs were owned 
by staff or students at Texas A&M University. All 54 dogs were judged to be healthy 
on physical examination and owners did not report any clinical signs on the provided 
questionnaire. Serum concentrations of canine trypsin-like immunoreactivity, canine 
pancreatic lipase immunoreactivity, canine C-reactive protein, cobalamin, and folate 
were measured in all samples at the Gastrointestinal Laboratory at Texas A&M 
University and the results were all within the reference ranges. Serum cNE was within 
the working range of the assay (1,100 to 41,500 µg/L) in 5 of the 54 dogs (9.3%), 
with concentrations ranging from 1,420.6 to 3,400 µg/L, and a median of 1,099 µg/L 
(Table 11). 
The reference range determined by the lower 95th percentile in these 54 clinically 
healthy dogs was < 1,631 µg/L (Figure 13). 
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Table 11: Serum cNE concentrations in 54 healthy dogs.  
This table shows the serum cNE concentrations in 54 healthy dogs. Of the 54 dogs, 49 
had undetectable serum cNE concentrations (<1100 µg/L) of the ELISA. In the 
remaining 5 dogs with measurable cNE concentrations, serum concentrations ranged 
from 1,420.6 µg/L to 3,400 µg/L (displayed in bold numbers). The median serum cNE 
concentration was 1099 µg/L. 
 
 
Healthy dogs  Serum cNE   Healthy dogs Serum cNE 
sample # µg/L   sample # µg/L 
 
working range  
1100 µg/L-41500 µg/L     
working range  
1100 µg/L-41500 µg/L   
     
1 1099   28 2344.0 
2 1099   29 1420.6 
3 1099   30 1099 
4 1099   31 1099 
5 1099   32 1241.3 
6 1099   33 3400.3 
7 1099   34 1099 
8 1099   35 1099 
9 1099   36 1099 
10 1099   37 1099 
11 1099   38 1099 
12 1099   39 1099 
13 1099   40 1099 
14 1099   41 1099 
15 1099   42 1099 
16 1099   43 1099 
17 1099   44 1099 
18 1099   45 1099 
19 1099   46 1099 
20 1099   47 1099 
21 1099   48 1099 
22 1099   49 1099 
23 1099   50 1099 
24 2022.0   51 1099 
25 1099   52 1099 
26 1099   53 1099 
27 1099   54 1099 
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Figure 13: Serum cNE concentrations in 54 healthy dogs. 
This graph shows the serum cNE concentrations in 54 healthy dogs. In 49 of the 54 
dogs serum cNE were below the working range of the ELISA, while only 5 dogs had 
serum cNE concentrations ranging from 1,420.6 µg/L to 3,400 µg/L. The reference 
range, determined by the lower 95th percentile in these 54 healthy dogs, was < 1,631 
µg/L. 
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4.6. Serum canine neutrophil elastase concentrations in dogs with   
gastrointestinal disease or pancreatitis 
Serum cNE concentrations were measured by cNE ELISA in 97 dogs with 
gastrointestinal disease (n=56) or pancreatitis (n=41). The dogs were divided into 4 
groups based on their diagnosis. Of the 97 dogs, 28 were diagnosed with 
lymphocytic-plasmacytic enteritis (group 1), 10 with eosinophilic enteritis (group 2), 
and 18 with lymphocytic-plasmacytic gastritis (group 3). The diagnosis was based on 
histopathologic evaluation of biopsy samples. Group 4 consisted of 41 dogs with 
pancreatitis. Diagnosis of pancreatitis was based on an increased serum cPLI 
concentration (> 200 µg/L). Table 12 shows the cNE concentration for each dog in the 
four disease groups, as well as the median, the range and the percentage of dogs with 
measurable cNE concentrations. Canine NE was detectable in 17.9% (5 out of 28) of 
the dogs with lymphocytic-plasmacytic enteritis (group 1), with a median serum cNE 
of 1,099 µg/L, ranging from 1,099 µg/L to 10,396 µg/L. Eighty percent (8 out of 10) 
of the dogs with eosinophilic enteritis (group 2) had detectable cNE concentrations, 
with a median of 2,200 µg/L, and a range from 1,099 µg/L to 7,246 µg/L. Of the 18 
dogs with lymphocytic-plasmacytic gastritis (group 3) 11.1% (2 out of 18) had 
detectable cNE concentrations, with a median of 1,099 µg/L, ranging from 1,099 µg/L 
to 1,543.8 µg/L. Finally, of the 41 dogs with pancreatitis (group 4) 53.7% (22 out of 
41) had detectable cNE concentrations, with a median of 1,719 µg/L, and a range 
from 1,099 µg/L to 24,240 µg/L. The percentage of dogs with a detectable serum cNE 
concentration in each group is graphically displayed in Figure 14. Figure 15 shows the 
percentage of dogs with serum cNE concentrations above the reference range. Figure 
16 shows the 4 different groups compared with each other 
Statistical analysis using the Kruskal-Wallis test for nonparametric comparison 
showed a significant difference between the mean serum cNE concentrations and the 
disease group each animal was assigned to (p<0.0001). The Dunn’s post test for 
multiple comparisons showed that the median serum cNE concentration was 
significantly higher in dogs with eosinophilic enteritis compared to healthy dogs 
(p<0.05). In addition, dogs with pancreatitis had a significantly higher median serum 
cNE concentration compared to healthy dogs (p<0.01), dogs with eosinophilic 
enteritis had a significantly higher median serum cNE concentration compared to 
dogs with lymphocytic-plasmacytic enteritis (p<0.05), dogs with pancreatitis had a 
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significantly higher median serum cNE concentration compared to dogs with 
lymphocytic-plasmacytic enteritis (p<0.05), and dogs with gastritis had a significantly 
higher median serum cNE concentration compared to dogs with eosinophilic enteritis 
(p<0.05). Finally dogs with pancreatitis had a significantly higher median serum cNE 
concentration than dogs with gastritis (p<0.05; Table 13).  
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Table 12: Serum cNE concentrations in 68 dogs with gastrointestinal disease or 
pancreatitis. This table shows serum cNE concentrations for 68 dogs with 
gastrointestinal disease or pancreatitis. The dogs were divided into 4 groups based on 
their final diagnosis. Values in bold represent values above the reference range 
(reference range: <1,630 µg/L). The total number of dogs in each group, the median, 
the range, and the percentage of dogs with measurable cNE concentrations are 
presented in this table. Note the working range of the assay: 1,099 µg/L to 41,500 
µg/L. 
Dog # 
Lymphocytic-
plasmacytic 
enteritis    
Eosinophilic 
enteritis   
Lymphocytic-
plasmacytic 
gastritis   
Pancreatitis 
 
Pancreatitis 
 
 cNE µg/L   cNE µg/L   cNE µg/L   cNE µg/L cNE µg/L 
                 
1 1099   1099   1543.8   22910.7 1719.4 
2 1099   2190.0   1099   2454.2 1099 
3 1099   2886.0   1099   1099 4695.6 
4 10396.0   2210.0   1099   3125.3 24242.3 
5 2948.5   7148.0   1099   1099 1099 
6 1099   7246.0   1099   1099 12711.3 
7 1099   1099   1099   16559.7 12700.9 
8 1827.3   1643.0   1099   1193.8 9125.1 
9 1099   7144.0   1099   1099 16977 
10 1099   2116.0   1363.8   1099 1099 
11 1099       1099   1099 1099 
12 1099       1099   5510.7 11802.7 
13 1099       1099   5290.8 1099 
14 1099       1099   4383.8  
15 1099       1099   1099  
16 1099       1099   1099  
17 2976.0       1099   1099  
18 1099       1099   12108.8  
19 1099           1099  
20 1099           17174.8  
21 1099           1099  
22 1110.0           8271.1  
23 1099           1099  
24 1099           8045.9  
25 1099           1099  
26 1099           1099  
27 1099           5487.8  
28 1099           16111.3  
                 
Number 
of dogs 28   10   18    41 
Median 1099   2200.0   1099    1719.4 
Min 1099   1099   1099    1099 
Max 10396.0   7246.0   1543.8    24242.3 
% of 
total 17.9   80.0   11.1    53.7 
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Figure 14: Percentage of dogs with serum cNE concentrations within the 
working range of the assay in 4 disease groups and a group of healthy dogs. 
This figure shows the percentage of dogs with detectable serum cNE concentrations in 
each group. Serum cNE concentrations were detected in 9.3% (5 out of 54) of healthy 
dogs, 17.9% (5 out of 28) of dogs with lymphocytic-plasmacytic enteritis, 80.0% (8 
out of 10) of dogs with eosinophilic enteritis, 11.1% (2 out of 18) of dogs with 
lymphocytic-plasmacytic gastritis, and 53.7% (22 out of 41) of dogs with pancreatitis. 
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Figure 15: Percentage of dogs with serum cNE concentrations above the 
reference range in 4 disease groups and a group of healthy dogs. 
This figure shows the percentage of dogs in each group with cNE concentrations 
above the upper limit of the reference range. Serum cNE concentrations were above 
the upper limit of the reference range in 5.7% (3 out of 54) healthy dogs, 14.3% (4 out 
of 28) dogs with lymphocytic-plasmacytic enteritis, 80.0% (8 out of 10) dogs with 
eosinophilic enteritis, 0% (0 out of 18) dogs with lymphocytic-plasmacytic gastritis, 
and 53.7% (22 out of 41) of dogs with pancreatitis. 
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Figure 16: Comparison of serum cNE concentrations between healthy dogs and 
diseased dogs. 
This figure shows serum cNE concentrations in 54 healthy dogs, 28 dogs with 
lymphocytic-plasmacytic enteritis (median cNE concentration: 1,099 µg/L), 10 dogs 
with eosinophilic enteritis (median cNE concentration: 2,200 µg/L), 18 dogs with 
lymphocytic-plasmacytic gastritis (median cNE concentration: 1,099 µg/L), and 41 
dogs with pancreatitis (median cNE concentration: 1,719.4 µg/L). The solid line 
indicates the upper limit of the reference range for this assay (1,631 µg/L). 
Statistical analysis using the Kruskal-Wallis test for nonparametric comparison was 
significant (p<0.0001).  
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Table 13: Results for the Dunn’s post test, multiple comparisons. 
This table shows the results for the statistical comparison of the 5 different groups: 
healthy, lymphocytic-plasmacytic enteritis, eosinophilic enteritis, lymphocytic-
plasmacytic gastritis, and pancreatitis. The Dunn’s post test for multiple comparisons 
was used for this statistical analysis. 
 
 
 
Dunn's Multiple Comparison Test for: 
 
  
P value: 
   
 
healthy dogs versus dogs with  
lymphocytic-plasmacytic enteritis 
 
  
not significant 
 
healthy dogs versus  
dogs with eosinophilic enteritis 
 
  
P<0.05 
 
healthy dogs versus  
dogs with lymphocytic-plasmacytic gastritis 
 
  
not significant 
 
healthy dogs versus  
dogs with pancreatitis 
 
  
P<0.01 
 
dogs with lymphocytic-plasmacytic enteritis versus 
dogs with eosinophilic enteritis 
 
  
P<0.05 
 
dogs with lymphocytic-plasmacytic enteritis versus 
dogs with lymphocytic-plasmacytic gastritis 
 
  
not significant 
 
dogs with lymphocytic-plasmacytic enteritis versus 
dogs with pancreatitis 
 
  
P<0.05 
 
dogs with eosinophilic enteritis versus  
dogs with lymphocytic-plasmacytic gastritis 
 
  
P<0.05 
 
dogs with eosinophilic enteritis versus  
dogs with pancreatitis 
 
  
not significant 
 
dogs with lymphocytic-plasmacytic gastritis versus  
dogs with pancreatitis 
 
  
P<0.05 
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5.    DISCUSSION  
5.1.    Purification of canine neutrophil elastase 
Canine neutrophil elastase (cNE) was successfully purified from dog blood. The 
described purification protocol reproducibly resulted in cNE of high purity as shown 
by SDS PAGE (Figure 4), as well as by Agilent 2100 bioanalysis in combination with 
the Protein 50 Lab-Chip® kit (Figure 7). 
The purification of cNE from ascitic fluid of dogs with experimentally induced 
peritonitis has previously been reported (Berlov et al., 2001; Delshammar et al., 
1976). Due to the invasiveness of the described procedure to induce peritonitis, blood 
was chosen as a neutrophil source in this study. Different protocols for the isolation of 
neutrophils from blood have previously been described. These include density 
gradient centrifugation using various media, such as Percoll™ (Gruber et al., 1990), 
Polymorphprep™ (Ferrante et al., 1980), and Dextran T (Boudier et al., 1982). In this 
study these different protocols were evaluated for their yield and purity, as well as 
their cost efficiency and time factor, and it was concluded that Dextran-T was the 
most useful protocol. Berlov et al., as well as Delshammar et al. used cation-exchange 
chromatography and gel filtration chromatography for the purification of cNE (Berlov 
et al., 2001; Delshammar et al., 1976). The results, as described by these investigators, 
could not be reproduced in our laboratory. In order to achieve a purification protocol 
with a high yield and high purity of the end product, multiple attempts using various 
chromatographic columns were made. The combined use of cation-exchange and size 
exclusion chromatography, as used by Berlov et al. and Delshammar et al., did not 
lead to pure cNE. By replacing the size exclusion column with a continuous-elution 
electrophoresis system (Bio-Rad Mini Prep Cell), which also separates proteins 
according to their size, we were able to separate cNE from all contaminating proteins. 
This protocol resulted in a purification yield of 9% (Table 3). Berlov et al. reported a 
purification yield of cNE from ascitic fluid of 43% (Berlov et al., 2001), while the 
yield reported by Delshammar et al. was 55% (Delshammar et al., 1976). Both 
investigators had a higher yield for the purification of cNE than was achieved by our 
protocol, which could be due to a difference in starting material for the purification 
(blood versus ascitic fluid). Our purification yield was similar to the yield reported for  
the purification of human NE from blood (6.4%) (Heck et al., 1985). 
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5.2.    Partial characterization of canine neutrophil elastase 
The molecular mass of cNE as determined by Agilent 2100 bioanalysis in 
combination with the Protein 50 Lab-Chip® kit was found to be 26,500 Dalton 
(Figures 7 and 8, Table 4). These results were slightly different from the results 
reported by Delshammar et al. and Berlov et al., who reported a molecular mass of 
24,800 Dalton (Delshammar et al., 1976) and 24,500-26,000 Dalton (Berlov et al., 
2001), respectively. This discrepancy could be explained by the fact that different 
methods were used to estimate the molecular mass of cNE in each study. Berlov et al. 
and Delshammar et al. used SDS gel electrophoresis for the determination of the 
molecular mass. When the molecular mass was calculated based on NuPAGE SDS 
gels (which are similar to the gels used by Delshammar et al. and Berlov et al.), our 
results were comparable to those of the previous studies. 
The isoelectric point of cNE was found to be between 8.5 and 9.0 (Figure 9), and was 
similar to that reported for porcine NE (>8.0) (Geiger et al., 1985). The isoelectric 
point of canine NE has not previously been reported. 
The approximate specific absorbance of cNE at 280 nm was determined to be 0.85 for 
a 1 mg/ml solution (Table 5) and has previously not been reported.  
The analysis of the sequence of the first 25 amino acids of the N-terminal end of cNE 
showed 100% homology to the amino acid sequence predicted by the nucleotide 
sequence available through the canine genome project. Comparison of the sequence of 
the first 25 amino acids of the N-terminal end of NE among different species revealed 
that cNE shows 100% homology to rat NE, 96% homology to mouse NE, and 92% to 
human NE (Table 6). However, it should be pointed out that only a portion of the 
amino acid sequence (the first 25 amino acids from the N-terminal end of a total of 
282 amino acids) of NE was compared. 
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5.3.    Production of anti-canine neutrophil elastase antibodies 
Antibodies are fundamental reagents for any ELISA, and in fact any immunoassay. 
For antibody production, a specific protein (in this case cNE) is injected into a host (in 
this case rabbits) stimulating the production of antibodies.  
Both polyclonal or monoclonal antibodies could be used in an ELISA. Because the 
production of monoclonal antibodies is associated with significant expense and 
expertise, and because monospecific polyclonal antibodies have been used 
successfully for immunoassays for the measurement of other analytes previously 
(Steiner et al., 2000), monospecific polyclonal antibodies were used in this project.  
The rabbit was chosen as a host species for this project, because the Gastrointestinal 
Laboratory at Texas A&M University has vast experience in raising antisera against 
different proteins using the rabbit as host for monospecific polyclonal antibody 
production. Also the production of antibodies in this species is less expensive 
compared to the production of antibodies in other species (e.g., sheep).  
The rabbit in this project showed a sufficient antibody titer after 4 vaccinations with 
pure cNE mixed with Freund’s complete and incomplete adjuvant (Figure 10). The 
amount of antibodies that were harvested after affinity chromatography of the 
antiserum was sufficient for the development and validation of the cNE ELISA. 
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5.4.    Development and validation of an ELISA for the measurement of canine 
neutrophil elastase 
A direct sandwich ELISA for the measurement of NE in canine serum samples was 
successfully developed and validated. In a direct sandwich ELISA, an antibody is 
attached to the solid phase to capture the antigen (in this case cNE). The bound 
antigen is then detected using an enzyme labeled antibody (Crowther, 1995). The 
capture antibody and the enzyme labeled antibody can be from the same antiserum. 
However, the antigen must have at least two epitopes (Crowther, 1995). Also, the 
polyclonal antibody must contain at least 2 clones of antibodies that are directed 
against a different epitope of the antigen. 
Validation of the ELISA was performed by determination of sensitivity, linearity, 
accuracy, and reproducibility. Specific goals for these performance characteristics of 
the assay were outlined and included: observed to expected ratios for dilutional 
parallelism and spiking recovery between 80 to 120% and coefficients of variation for 
intra- and inter-assay variability between 10 to 15% (Steiner et al., 2000). In 
literature, no rationales are given for these target values (Steiner et al., 2000). While 
there is little evidence to suggest the validity of these targeted performance indices, 
many immunoassays that have been proved to be clinically relevant have shown 
performance indices meeting these criteria (Melgarejo et al., 1993; Steiner et al., 
2000; Steiner et al., 2001).  
The assay sensitivity was determined to be 1,100 µg/L cNE. Evaluation of dilutional 
parallelism of the ELISA indicated acceptable linearity for clinical use. All 4 samples 
had observed to expected ratios between 85.4% and 122.3% (Table 7), which is 
considered acceptable for clinical application, as mentioned above. Results of spiking 
recovery showed acceptable accuracy of the assay (Table 8). In a single sample spiked 
with 20 µg/L of cNE, a low recovery (27.1%) was observed. An explanation for this 
result is the low concentration of cNE in this specific sample, which was below the 
sensitivity range of the assay and therefore resulted in an inaccurate result. The intra-
assay variability for 4 different serum samples was between 13.4 to 16.8% with a 
mean (±SD) of 15.1% (±1.6%; Table 9). The inter-assay variability for 4 different 
serum samples ranged from 10.5 to 15.4% with a mean (±SD) of 13.9% (±2.3%; 
Table 10). The results for the intra- and inter-assay variability’s were considered 
acceptable for clinical application, by the guidelines mentioned above. 
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5.5. Serum cNE concentrations in clinically healthy dogs 
A reference range of <1,631 µg/L for serum cNE was established based on results 
from 54 clinically healthy dogs using the lower 95th percentile. Serum cNE 
concentrations were only detectable in 9.3% of healthy control dogs (Table 11). 
The established reference range for the cNE ELISA is higher than what has been 
reported for human NE, which has be determined to be between 20 and 180 µg/L 
(Neumann et al., 1984). It has to be pointed out, however, that the assay for human 
NE measures the NE/α1-proteinase inhibitor complex (Neumann et al., 1984) and, 
therefore, it is not possible to compare the reference ranges for these two different 
species. 
 
 
5.6.    Serum cNE concentrations in diseased dogs 
In human patients with IBD, neutrophilic infiltration of the gastrointestinal mucosa is 
a common histological finding (Andus et al., 1993; Dwarakanath et al., 1997). It is 
reliably seen in patients with ulcerative colitis and also frequently observed in patients 
with Crohn’s disease (Adeyemi et al., 1985). Serum NE concentrations correlated 
significantly with Crohn’s disease activity index scores in human IBD patients 
(Adeyemi et al., 1985). In order to determine the usefulness of serum cNE 
concentrations in dogs with IBD, we evaluated serum samples from 38 dogs with 
histopathological evidence of IBD. In addition, and because neutrophilic infiltration 
and subsequent cNE production can take place in many organs other than the 
intestine, cNE concentrations were measured in the serum of 41 dogs with cPLI 
concentrations diagnostic of pancreatitis and 18 dogs with lymphocytic-plasmacytic 
gastritis. Inflammatory bowel disease (lymphocytic-plasmacytic enteritis and 
eosinophilic enteritis), as well as lymphocytic-plasmacytic gastritis, were diagnosed 
based on the combination of clinical signs and histopathological evaluation of 
endoscopically collected biopsies. 
Statistical analysis of the data was performed with a statistical software package using 
the Kruskal-Wallis test for nonparametric comparison with the Dunn’s post test for 
multiple comparisons. 
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The median concentration of serum cNE in dogs with lymphocytic-plasmacytic 
enteritis did not differ significantly from that of clinically healthy dogs. Only 2 of the 
28 dogs with lymphocytic-plasmacytic enteritis had detectable serum cNE 
concentrations. The concentrations of serum cNE in these 2 dogs were within the 
reference range for the assay. This finding can be explained by the fact that, by 
definition, the predominant inflammatory cell types in lymphocytic-plasmacytic 
enteritis are lymphocytes and plasmacytes, which are not capable of producing NE. 
Dogs with eosinophilic enteritis had significantly higher median concentration of 
serum cNE compared with healthy control dogs. In 8 of 10 dogs with eosinophilic 
enteritis, serum cNE concentrations were above the established reference range for the 
assay. One explanation for this finding is that the pathologists, who evaluated the 
intestinal biopsies from these dogs, frequently mentioned neutrophilic infiltration in 
combination with eosinophilic infiltration. Another possible explanation is that 
eosinophils are capable of producing NE or a protein that is identical with the 
chemical properties of NE. Additional studies are necessary to further evaluate this 
issue. 
Median serum cNE concentrations were significantly higher in dogs with pancreatitis, 
compared to healthy control dogs. In 21 out of 41 dogs diagnosed with pancreatitis 
based on an elevated serum cPLI concentration, serum cNE concentrations were 
above the reference range. This finding can be explained by the fact that the pancreas 
is frequently infiltrated with neutrophils during pancreatitis (Gross et al., 1990), and 
suggests that serum cNE concentrations cannot be used as a  specific marker for IBD. 
Median serum cNE concentrations in dogs with eosinophilic enteritis were 
significantly higher than those in dogs with lymphocytic-plasmacytic enteritis. This 
suggests that the measurement of serum cNE concentration may be helpful to 
differentiate between eosinophilic and lymphocytic-plasmacytic enteritis. However, a 
larger number of dogs need to be evaluated before reaching a conclusive answer to the 
question whether or not serum cNE could be clinically useful in the diagnosis of 
eosinophilic enteritis. 
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5.6. Conclusion 
 
In conclusion, canine neutrophil elastase has been successfully purified from dog 
blood. An ELISA for the measurement of cNE in dog serum was established and 
validated. Canine neutrophil elastase concentration of 56 serum samples from 
diseased dogs were measured and statistically analyzed. These data demonstrate that 
there is activation of neutrophils, resulting in the release of NE in most dogs with 
eosinophilic enteritis as well as in many dogs with pancreatitis. Also, the median cNE 
concentration in serum is significantly higher in dogs with eosinophilic enteritis and 
pancreatitis, when compared to healthy control dogs, and also when compared to dogs 
with lymphocytic-plasmacytic enteritis. However, due to the overlap between patients 
with eosinophilic enteritis and other inflammatory conditions (e.g. pancreatitis), 
serum cNE concentration is not specific for intestinal neutrophilic inflammation. 
Further studies are needed to evaluate the usefulness of this assay for clinical 
applications, such as monitoring the disease severity and progression in patients with 
known inflammatory conditions of the intestinal mucosa.  
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6.    SUMMARY 
Purification and Partial Characterization of Canine Neutrophil 
Elastase and the Development of an Immunoassay for the 
Measurement of Canine Neutrophil Elastase in Serum 
 
Canine neutrophil elastase (cNE) belongs to a group of serine proteinases and is a 
constituent of azurophil granules of neutrophils. It has previously been reported that 
the concentration of neutrophil-derived proteins in serum and feces can be used as a 
marker for intestinal inflammation in humans. The aim of this study was to develop a 
rapid and reproducible protocol for the purification of cNE from dog blood, to 
partially characterize cNE, to produce anti-cNE antibodies, to develop and validate an 
ELISA for the measurement of neutrophil elastase, and to compare serum cNE 
concentrations between healthy dogs and dogs with either gastrointestinal disease or 
pancreatitis.  
An efficient and reproducible protocol for the isolation of neutrophils, the extraction 
of neutrophil elastase from the neutrophilic granules, and further purification of the 
protein was established. Some physiological properties of the protein were evaluated. 
An ELISA for cNE was developed and validated and a reference range was 
established. Finally, the serum concentrations of canine neutrophil elastase were 
compared between healthy dogs and those with gastrointestinal disease or 
pancreatitis.    
The molecular mass of cNE was estimated to be 26,500 Dalton. Isoelectric focusing 
showed an isoelectric point between 8.5 and 9.0. The N-terminal amino acid sequence 
of the first 25 residues was Ile-Val-Gly-Gly-Arg-Pro-Ala-Gln-Pro-His-Ala-Trp-Pro-
Phe-Met-Val-Ser-Leu-Gln-Arg-Arg-Gly-Gly-His-Phe. The sequence showed 100% 
homology with the N-terminal amino acid sequence predicted by the nucleotide 
sequence available through the canine genome project. The approximate specific 
absorbance of cNE at 280 nm was determined to be 0.85 for a 1 mg/ml solution. The 
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ELISA for measuring the concentration of cNE in canine serum was sufficiently 
sensitive, linear, accurate, precise, and reproducible for clinical use. Canine NE could 
be detected in 17.9% of the dogs with lymphocytic-plasmacytic enteritis, 80% of the 
dogs with eosinophilic enteritis, 11.1% of the dogs with lymphocytic-plasmacytic 
gastritis and in 53.7% of the dogs with pancreatitis. The mean serum cNE 
concentration was significantly higher in dogs with eosinophilic enteritis and 
pancreatitis, when compared to healthy control dogs or dogs with lymphocytic-
plasmacytic enteritis.  
In conclusion serum cNE concentration can serve as a marker for neutrophilic 
infiltration. Further studies are needed to evaluate the clinical usefulness of this assay. 
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7.    ZUSAMMENFASSUNG 
Reinigung und Teilcharakterisierung von caniner 
neutrophiler Elastase und die Entwicklung eines 
Immunoassays zur Messung der Konzentration der 
neutrophilen Elastase im Serum 
 
Canine neutrophile Elastase (cNE) gehört zu der Gruppe der serinen Proteinasen und 
ist in den azurophilen Granula der neutrophilen Granulozyten eingelagert. Es gab 
Berichte wonach die Konzentration von Proteinen, die aus den neutrophilen 
Granulozyten stammen, in Serum und Kot gemessen werden können und als Marker 
für eine Infiltration der Darmmukosa mit Entzündungszellen beim Menschen 
verwendet werden können. Der Zweck dieser Studie war es, ein schnelles und 
reproduzierbares Protokoll für die Reinigung von cNE aus Hundeblut zu erstellen, die 
Teilcharakterisierung von cNE, die Produktion von Antikörpern gegen cNE, die 
Entwicklung und Validierung eines Immunoassays, sowie die Messung und den 
Vergleich der Konzentration von cNE im Serum von gesunden Hunden und Hunden 
mit  gastrointestinalen Erkrankungen oder Pankreatitis. 
Ein effizientes und wiederholbares Protokoll für die Trennung von neutrophilen 
Granulozyten, die Extraktion von neutrophiler Elastase aus den azurophilen Granula, 
sowie die Reinigung des Proteins wurden erstellt. Einige physiologische 
Eigenschaften von cNE wurden ebenfalls ermittelt. 
Ein ELISA für die Messung von cNE wurde entwickelt und validiert, sowie ein 
Referenzbereich ermittelt. Schließlich wurde die Konzentration von cNE im Serum 
von gesunden Hunden mit der von Hunden mit gastrointestinalen Erkrankungen oder 
Pankreatitis verglichen. 
Das molekulare Gewicht von cNE wurde auf 26.500 Dalton geschätzt. Die 
isoelektrische Fokussierung ergab einen isoelektrischen Punkt zwischen 8,5 und 9,0. 
Die N-terminale Aminosäuresequenz der ersten 25 Aminosäuren war Ile-Val-Gly-
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Gly-Arg-Pro-Ala-Gln-Pro-His-Ala-Trp-Pro-Phe-Met-Val-Ser-Leu-Gln-Arg-Arg-Gly-
Gly-His-Phe. Diese Sequenz zeigte 100% Übereinstimmung  mit der vom Hunde-
Genom-Programm veröffentlichten Nukleotidsequenz abgeleiteten N-terminalen 
Sequenz. Der spezifische Absorptionskoeffizient von cNE bei 280 nm wurde als 0,85 
für eine 1 mg/ml-Lösung ermittelt. Der entwickelte ELISA zur Messung der 
Konzentration von cNE in Hundeserum ist ausreichend sensitiv, linear, akkurat,  
sowie genau und reproduzierbar. Canine NE konnte bei 17,9 % der Hunde mit 
lymphoplasmazellulärer Enteritis, bei 80 % der Hunde mit eosinophiler Enteritis, 
1,1 % der Hunde mit lymphoplasmazellulärer Gastritis und 53,7 % der Hunde mit 
Pankreatitis gemessen werden. Der Mittelwert der cNE-Konzentration im Serum war 
signifikant höher bei Hunden mit eosinophiler Enteritis und Hunden mit Pankreatitis 
als bei gesunden Hunden oder Hunden mit lymphoplasmazellulärer Enteritis. 
Abschließend kann festgestellt werden, dass die cNE Konzentration als Marker für 
Erkrankungen eingesetzt werden kann, die mit einer Infiltration mit 
Entzündungszellen einhergehen. Weitere Studien sind notwendig um den klinischen 
Nutzen dieses Assays zu prüfen. 
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  A.3.     List of Buffer  
Buffers used during purification of cNE: 
• Extraction buffer: 
0.02 M Tris, 1 M NaCl, 0.005% Tween, pH 8.5 
 
• Solution for blood sedimentation: 
60 mg/ml Dextran 500, 9 mg/ml NaCl 
 
• Buffer A for cation-exchange chromatography: 
0.05 M sodium acetate, 0.05 M NaCl, pH 5.0 
 
Buffer for continuous elution-electrophoresis: 
• Resolving gel buffer 
1.5 M Tris-HCl, pH 8.8 
 
• Stacking gel buffer  
0.5 M Tris-HCl, pH 6.8 
 
• Gel casting Buffer 
0.375 M Tris-HCl, pH 8.8 
 
• Running/Elution buffer 
0.025 M Tris-HCl, 0.192 M glycine, 0.1% SDS, pH 8.3 
 
• Sample buffer  
0.06 M Tris-HCl, 2% SDS, 5% beta-mercaptoethanol, 25% glycerol (w/v) and 
0.01% bromophenol blue, pH 6.8 
 
• Sodium-dodecyl-sulfate-polyacrylamide gel electrophoresis buffer: 
MES running buffer 
1 M 2-(N-morpholino) ethane sulfonic acid, 1 M Tris-base, 70 mM SDS, 21 mM 
EDTA, pH 7.3 
 
APPENDIX 
 88 
• NuPAGE® SDS sample buffer 
4 g sucrose + 0.68 g Tris-base + 0.67 g Tris-HCl + 0.8 g SDS + 0.006 g EDTA + 
0.75 ml Serva blue G250 + 0.25 ml Phenol red + ultra pure water to 10 ml 
 
 
Buffers used for cNE ELISA: 
• Sample buffer, TBS+BSA+Tween 
50 mM Tris-base, 0.14 M NaCl, 1% BSA, 0.05% Tween, pH 8.0 
 
• ELISA wash buffer, TBS 
50 mM Tris-base, 0.14 M NaCl; pH 8.0 
 
• Binding buffer, sodium carbonate-bicarbonate buffer 
0.2 M sodium carbonate-bicarbonate, pH 9.4 
 
• ELISA stopping solution 
17.4 M acetic acid, 2 N sulfuric acid 
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